127 results on '"Bilgin A"'
Search Results
2. POS0944 PREDICTORS OF SUSTAINED REMISSION IN PEOPLE WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIOLOGIC DRUGS
- Author
-
Farisogullari, B., primary, Yardimci, G. K., additional, Bilgin, E., additional, Bolek, E. C., additional, Duran, E., additional, Ayan, G., additional, Özsoy, Z., additional, Sandal Uzun, G., additional, Ekici, M., additional, Unaldi, E., additional, Kiliç, L., additional, Akdoğan, A., additional, Karadag, O., additional, Bilgen, Ş. A., additional, Kiraz, S., additional, Ertenli, A. İ., additional, Kalyoncu, U., additional, and Machado, P. M., additional
- Published
- 2022
- Full Text
- View/download PDF
3. AB0912 Swollen and tender joints improvement in the randomized controlled trials of psoriatic arthritis
- Author
-
Ekici, M., primary, Unaldi, E., additional, Ayan, G., additional, Bilgin, E., additional, and Kalyoncu, U., additional
- Published
- 2022
- Full Text
- View/download PDF
4. POS1187 DO IMMUNOSUPPRESSIVE AGENTS AFFECT IGRA TESTS IN PATIENTS WITH RHEUMATOID ARTHRITIS?
- Author
-
Özsoy, Z., primary, Özdemir, A., additional, Ekici, M., additional, Bilgin, E., additional, Kiliç, L., additional, Kiraz, S., additional, Saribaş, Z., additional, Şener, B., additional, and Karadag, O., additional
- Published
- 2022
- Full Text
- View/download PDF
5. AB0353 bDMARD CHOICES FOR INFLAMMATORY ARTHRITIS WITH CHRONIC KIDNEY DISEASE; HUR-BIO REAL-LIFE REGISTRY
- Author
-
Sandal Uzun, G., primary, Taghiyeva, A., additional, Çakir, İ. Y., additional, Moral, K., additional, Bilgin, E., additional, Yardimci, G. K., additional, Farisogullari, B., additional, Bolek, E. C., additional, Duran, E., additional, Özsoy, Z., additional, Ayan, G., additional, Ekici, M., additional, Unaldi, E., additional, Kiliç, L., additional, Akdoğan, A., additional, Karadag, O., additional, Bilgen, Ş. A., additional, Kiraz, S., additional, Ertenli, A. İ., additional, and Kalyoncu, U., additional
- Published
- 2022
- Full Text
- View/download PDF
6. POS1184 EPIDEMIOLOGICAL CHARACTERISTICS OF VIRAL HEPATITIS IN PATIENTS WITH RHEUMATIC DISEASES – IMPLICATIONS FROM TREASURE DATABASE
- Author
-
Ersözlü, D., primary, Ekici, M., additional, Coşkun, B. N., additional, Badak, S. Ö., additional, Bilgin, E., additional, Kalyoncu, U., additional, Yağiz, B., additional, Pehlivan, Y., additional, Küçükşahin, O., additional, Erden, A., additional, Solmaz, D., additional, Atagündüz, P., additional, Kimyon, G., additional, Bes, C., additional, Colak, S., additional, Mercan, R., additional, Kaşifoğlu, T., additional, Emmungil, H., additional, Kanitez, N. A., additional, Ateş, A., additional, Koca, S. S., additional, Kiraz, S., additional, and Ertenli, A. İ., additional
- Published
- 2022
- Full Text
- View/download PDF
7. POS0977 ASSOCIATION OF DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER AND AXIAL SPONDYLOARTHRITIS WITH THE M694V MUTATION
- Author
-
Kiraci, M., primary, Bilgin, E., additional, Duran, E., additional, Farisogullari, B., additional, Bolek, E. C., additional, Yardimci, G. K., additional, Özsoy, Z., additional, Ayan, G., additional, Sandal Uzun, G., additional, Akbaba, T. H., additional, Peynircioglu, B. B., additional, Karadag, O., additional, Akdoğan, A., additional, Bilgen, Ş. A., additional, Kiraz, S., additional, Ertenli, A. İ., additional, Kalyoncu, U., additional, and Kiliç, L., additional
- Published
- 2022
- Full Text
- View/download PDF
8. AB0355 THE DIFFERENCES BETWEEN THE FIRST PREFERRED BIOLOGICAL DMARD AND THE DRUG SURVIVAL IN GERIATRIC AND YOUNGER ADULT POPULATION WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS: TREASURE REAL-LIFE DATA
- Author
-
Gönüllü, E., primary, Kalyoncu, U., additional, Yağiz, B., additional, Ateş, A., additional, Küçükşahin, O., additional, Yaşar Bilge, Ş., additional, Kanitez, N. A., additional, Çinar, M., additional, Ersözlü, D., additional, Mercan, R., additional, Akar, S., additional, Kaşifoğlu, T., additional, Coşkun, B. N., additional, Koca, S. S., additional, Bilgin, E., additional, Yazisiz, V., additional, Dalkiliç, E., additional, Yilmaz, R., additional, Kimyon, G., additional, Türk, S. M., additional, Erden, A., additional, Bes, C., additional, Emmungil, H., additional, Pehlivan, Y., additional, Ertenli, A. İ., additional, and Kiraz, S., additional
- Published
- 2022
- Full Text
- View/download PDF
9. AB0416 CARDIOVASCULAR EVENT, VENOUS THROMBOEMBOLIZM, AND INFECTION RISK WITH TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS AGED ≥ 60 YEARS
- Author
-
Duran, E., primary, Unaldi, E., additional, Bilgin, E., additional, Bolek, E. C., additional, Yardimci, G. K., additional, Farisogullari, B., additional, Özsoy, Z., additional, Ayan, G., additional, Sandal Uzun, G., additional, Ekici, M., additional, Kiliç, L., additional, Akdoğan, A., additional, Karadag, O., additional, Bilgen, Ş. A., additional, Ertenli, A. I., additional, Kalyoncu, U., additional, and Kiraz, S., additional
- Published
- 2022
- Full Text
- View/download PDF
10. POS1085 FREQUENCY OF DYSLIPIDEMIA AND COMPLIANCE WITH THE TREATMENT IN PsA PATIENTS USING bDMARDs
- Author
-
Gezerer, N. E., primary, Ayan, G., additional, Bilgin, E., additional, Yardimci, G. K., additional, Bolek, E. C., additional, Farisogullari, B., additional, Duran, E., additional, Özsoy, Z., additional, Sandal Uzun, G., additional, Ekici, M., additional, Unaldi, E., additional, Kiliç, L., additional, Akdogan, A., additional, Karadag, O., additional, Bilgen, Ş. A., additional, Kiraz, S., additional, Ertenli, A. İ., additional, and Kalyoncu, U., additional
- Published
- 2022
- Full Text
- View/download PDF
11. AB0808 Costovertebral, Costotransverse, Sternoclavicular and Manubriosternal Joint Involvement in Spondyloarthritis: Preliminary Results of Single Centre Experience
- Author
-
Ata, E. B., primary, Bilgin, E., additional, Durhan, G., additional, Ayan, G., additional, Ariyürek, M., additional, and Kalyoncu, U., additional
- Published
- 2022
- Full Text
- View/download PDF
12. AB0843 OSTEOPOROSIS IN PATIENTS WITH SPONDYLOARTHRITIS: DO WE NEED TO DO MORE?
- Author
-
Özsoy, Z., primary, Moral, K., additional, Yeşil, F., additional, Bilgin, E., additional, Bolek, E. C., additional, Yardimci, G. K., additional, Farisogullari, B., additional, Duran, E., additional, Ayan, G., additional, Sandal Uzun, G., additional, Ekici, M., additional, Unaldi, E., additional, Kiliç, L., additional, Akdoğan, A., additional, Karadag, O., additional, Bilgen, Ş. A., additional, Kiraz, S., additional, Ertenli, A. İ., additional, and Kalyoncu, U., additional
- Published
- 2022
- Full Text
- View/download PDF
13. AB0282 COMORBIDITIES ARE MORE IMPORTANT THAN JAK INHIBITORS: VENOUS THROMBOEMBOLISM IN RHEUMATOID ARTHRITIS
- Author
-
Sandal Uzun, G., primary, Bahap, M., additional, Yucel, O., additional, Kaygusuz, Y., additional, Bilgin, E., additional, Kiliç, L., additional, Akdoğan, A., additional, Karadag, O., additional, Bilgen, Ş. A., additional, Kiraz, S., additional, Ertenli, A. İ., additional, and Kalyoncu, U., additional
- Published
- 2022
- Full Text
- View/download PDF
14. AB0278 IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING bDMARDs, THE CHARLSON COMORBIDITY INDEX IS MORE PRONOUNCED THAN PSORIATIC ARTHRITIS
- Author
-
Sandal Uzun, G., primary, Tatar, O. D., additional, Gezerer, N. E., additional, Bilgin, E., additional, Yardimci, G. K., additional, Bolek, E. C., additional, Farisogullari, B., additional, Duran, E., additional, Özsoy, Z., additional, Ayan, G., additional, Ekici, M., additional, Unaldi, E., additional, Kiliç, L., additional, Kalyoncu, U., additional, Karadag, O., additional, Akdoğan, A., additional, Bilgen, Ş. A., additional, Kiraz, S., additional, and Ertenli, A. İ., additional
- Published
- 2022
- Full Text
- View/download PDF
15. POS0991 PREDICTORS OF DEVELOPMENT OF ADVANCED SPINAL ANKYLOSIS/BAMBOO SPINE IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM REAL-LIFE DATA
- Author
-
Farisogullari, B., primary, Yardimci, G. K., additional, Bilgin, E., additional, Bolek, E. C., additional, Duran, E., additional, Ayan, G., additional, Özsoy, Z., additional, Sandal Uzun, G., additional, Ekici, M., additional, Unaldi, E., additional, Kiliç, L., additional, Akdoğan, A., additional, Karadag, O., additional, Bilgen, Ş. A., additional, Kiraz, S., additional, Kalyoncu, U., additional, and Ertenli, A. İ., additional
- Published
- 2022
- Full Text
- View/download PDF
16. AB0774 Paradoxical reactions, especially psoriasis in rheumatology patients receiving biologic therapy from the Treasure database: a 5-year follow-up study
- Author
-
Yağiz, B., primary, Lermi, N., additional, Coşkun, B. N., additional, Dalkiliç, E., additional, Kiraz, S., additional, Ertenli, A. İ., additional, Bilgin, E., additional, Yilmaz, R., additional, Ateş, A., additional, Tufan, A., additional, Mercan, R., additional, Cinakli, H., additional, Akar, S., additional, Kaşifoğlu, T., additional, Türk, S. M., additional, Gönüllü, E., additional, Erden, A., additional, Bes, C., additional, Emmungil, H., additional, Kalyoncu, U., additional, and Pehlivan, Y., additional
- Published
- 2022
- Full Text
- View/download PDF
17. AB0940 Is psoriatic arthritis really seronegative?
- Author
-
Ayan, G., primary, Gezerer, N. E., additional, Bilgin, E., additional, Yardimci, G. K., additional, Bolek, E. C., additional, Farisogullari, B., additional, Duran, E., additional, Özsoy, Z., additional, Sandal Uzun, G., additional, Ekici, M., additional, Unaldi, E., additional, Kiliç, L., additional, Akdogan, A., additional, Karadag, O., additional, Bilgen, Ş. A., additional, Kiraz, S., additional, Ertenli, A. İ., additional, and Kalyoncu, U., additional
- Published
- 2022
- Full Text
- View/download PDF
18. POS0765 IS THERE ANY DIFFERENCE IN THE CLINICAL FEATURES AND OUTCOMES OF PROLIFERATIVE AND NON-PROLIFERATIVE FORMS OF LUPUS NEPHRITIS PROVEN BY BIOPSY?
- Author
-
Duran, E., primary, Yildirim, T., additional, Taghiyeva, A., additional, Bilgin, E., additional, Arici, M., additional, Saglam, A., additional, Özen, S., additional, Üner, M., additional, Erdem, Y., additional, Kalyoncu, U., additional, and Ertenli, A. I., additional
- Published
- 2022
- Full Text
- View/download PDF
19. AB0275 THE FREQUENCY, PREVALENCE OF CORONARY ARTERY DISEASE AND PRE-MATURE CAD IN PsA AND RA PATIENTS
- Author
-
Ayan, G., primary, Sandal Uzun, G., additional, Tatar, O. D., additional, Gezerer, N. E., additional, Bilgin, E., additional, Yardimci, G. K., additional, Bolek, E. C., additional, Farisogullari, B., additional, Duran, E., additional, Özsoy, Z., additional, Ekici, M., additional, Unaldi, E., additional, Kiliç, L., additional, Akdogan, A., additional, Karadag, O., additional, Bilgen, Ş. A., additional, Kiraz, S., additional, Ertenli, A. İ., additional, and Kalyoncu, U., additional
- Published
- 2022
- Full Text
- View/download PDF
20. POS0602 PULMONARY RHEUMATOID NODULES: DOES SEROLOGIC STATUS MATTER?
- Author
-
Sarikaya, Y., primary, Sandal Uzun, G., additional, Ata, E. B., additional, Arslan, S., additional, Ekici, M., additional, Durhan, G., additional, Bilgin, E., additional, Kalyoncu, U., additional, and Ariyürek, M., additional
- Published
- 2022
- Full Text
- View/download PDF
21. POS1087 THE RELATIONSHIP BETWEEN CHANGES IN PSORIATIC ARTHRITIS DISEASE ACTIVITY AND COMORBIDITIES IN PATIENTS TREATED WITH bDMARDs
- Author
-
Ayan, G., primary, Gezerer, N. E., additional, Bilgin, E., additional, Yardimci, G. K., additional, Bolek, E. C., additional, Farisogullari, B., additional, Duran, E., additional, Özsoy, Z., additional, Sandal Uzun, G., additional, Ekici, M., additional, Unaldi, E., additional, Kiliç, L., additional, Akdogan, A., additional, Karadag, O., additional, Bilgen, Ş. A., additional, Kiraz, S., additional, Ertenli, A. İ., additional, and Kalyoncu, U., additional
- Published
- 2022
- Full Text
- View/download PDF
22. POS1440 HEMATOLOGICAL MALIGNANCIES AND ANTI-TNF IN INFLAMMATORY ARTHRITIS: THE REAL LIFE DATA FROM THE HUR-BIO REGISTRY
- Author
-
Duran, E., primary, Öztürk, Z. Ö., additional, Bilgin, E., additional, Bolek, E. C., additional, Yardimci, G. K., additional, Farisogullari, B., additional, Özsoy, Z., additional, Ayan, G., additional, Sandal Uzun, G., additional, Ekici, M., additional, Unaldi, E., additional, Kiliç, L., additional, Akdoğan, A., additional, Karadag, O., additional, Bilgen, Ş. A., additional, Kiraz, S., additional, Kalyoncu, U., additional, and Ertenli, A. I., additional
- Published
- 2022
- Full Text
- View/download PDF
23. AB0277 DYSLIPIDEMIA TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS USING bDMARDs IS BETTER THAN PsA, BUT THERE IS STILL A WAY TO GO
- Author
-
Sandal Uzun, G., primary, Tatar, O. D., additional, Gezerer, N. E., additional, Bilgin, E., additional, Yardimci, G. K., additional, Bolek, E. C., additional, Farisogullari, B., additional, Duran, E., additional, Özsoy, Z., additional, Ayan, G., additional, Ekici, M., additional, Unaldi, E., additional, Kiliç, L., additional, Akdoğan, A., additional, Karadag, O., additional, Bilgen, Ş. A., additional, Kiraz, S., additional, Kalyoncu, U., additional, and Ertenli, A. İ., additional
- Published
- 2022
- Full Text
- View/download PDF
24. POS0601 CRANIOCERVICAL JUNCTION INVOLVEMENT ASSESSED BY COMPUTED TOMOGRAPHY AND/OR MAGNETIC RESONANCE IMAGING IN INFLAMMATORY ARTHRITIS: SINGLE CENTER CASE-CONTROL STUDY
- Author
-
Yalçinkaya, F., primary, Parlak, Ş., additional, Bilgin, E., additional, Karli Oğuz, K., additional, and Kalyoncu, U., additional
- Published
- 2022
- Full Text
- View/download PDF
25. AB0766 Biologic Drug Preferences of Turkish Rheumatologists in Spondiloartropathy Patients with Advanced Chronic Renal Disease
- Author
-
Mercan, R., primary, Tezcan, M. E., additional, Yağiz, B., additional, Ateş, A., additional, Küçükşahin, O., additional, Yasar Bilge, N. S., additional, Kanitez, N. A., additional, Gönüllü, E., additional, Yilmaz, S., additional, Ersözlü, D., additional, Solmaz, D., additional, Kaşifoğlu, T., additional, Coşkun, B. N., additional, Koca, S. S., additional, Bilgin, E., additional, Yazisiz, V., additional, Dalkiliç, E., additional, Yilmaz, R., additional, Kimyon, G., additional, Ayan, G., additional, Erden, A., additional, Bes, C., additional, Emmungil, H., additional, Pehlivan, Y., additional, Ertenli, A. İ., additional, Kiraz, S., additional, and Kalyoncu, U., additional
- Published
- 2022
- Full Text
- View/download PDF
26. AB1076 IS THERE AN ADDITIONAL IMPACT OF STIMULATING CD8+ LYMPHOCYTES TO DETECT LATENT TUBERCULOSIS IN PATIENTS WITH RHEUMATIC DISEASES?
- Author
-
Özsoy, Z., primary, Özdemir, A., additional, Ekici, M., additional, Eken, A., additional, Çakmak, F., additional, Bilgin, E., additional, Kiliç, L., additional, Ertenli, A. İ., additional, Saribaş, Z., additional, Karadag, O., additional, and Şener, B., additional
- Published
- 2022
- Full Text
- View/download PDF
27. POS0765 IS THERE ANY DIFFERENCE IN THE CLINICAL FEATURES AND OUTCOMES OF PROLIFERATIVE AND NON-PROLIFERATIVE FORMS OF LUPUS NEPHRITIS PROVEN BY BIOPSY?
- Author
-
E. Duran, T. Yildirim, A. Taghiyeva, E. Bilgin, M. Arici, A. Saglam, S. Özen, M. Üner, Y. Erdem, U. Kalyoncu, and A. I. Ertenli
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundLupus nephritis (LN), which occurs in 60-70% of patients with systemic lupus erythematosus, is a major determinant of morbidity and mortality. There still are many uncertain aspects in clinical, pathological, and prognostic characteristics about LN.ObjectivesWe aimed to compare clinical features, outcomes, and to define the predictive factors of complete renal response (CRR) in patients with proliferative and non-proliferative LN.MethodsPatients with SLE followed between 2014 and 2020 at Hacettepe University Hospitals and who had a kidney biopsy were the subject of the study. One hundred and sixteen patients whose kidney biopsy reported as LN were evaluated retrospectively. Clinical features, laboratory values at the time of kidney biopsy, histopathological forms of LN, and renal response (complete or partial) were recorded. The predictive factors for CRR during the two-year follow-up after induction therapy were analyzed.ResultsOf 116 (93 females, 23 males) patients, 95 (81.9%) were in the proliferative (class III and IV) and 21 (18.1%) were in the non-proliferative group (class II and V). In the proliferative group, elevated basal creatinine, median daily proteinuria, anti-dsDNA positivity, low C3 and C4, the presence of active urinary sediment, and median renal SLE Disease Activity Index (SLEDAI) scores at the time of kidney biopsy were significantly higher than non-proliferative group. During the two-year follow-up after LN diagnosis, 70 patients achieved CRR and time-to-CRR was similar for the groups (p=0.64, log-rank). The Cox proportional hazards model showed that achieving CRR was associated with female gender [HR: 2.15 (1.19-3.89 95% CI), p=0.011], newly diagnosed SLE with renal biopsy [2.15 (1.26-3.67), p=0.005], hypertension [0.40 (0.27-0.94), p=0.032], eGFR increase [1.01 (1.00-1.01), p=0.046], and presence of active urinary sediment [0.46 (0.22-0.96), p=0.039].ConclusionAchieving CRR was similar in both the proliferative and non-proliferative LN patients although certain laboratory parameters differed at onset. Our results indicated the importance of kidney biopsy in the decision-making of treatment of SLE patients with renal involvement and that the defined factors associated with CRR achievement help to predict good renal response.Table 1.Demographic, clinical characteristics, and outcomes of the patients with LNVariables*All patientsProliferative LNNon-Proliferative LNpn=116n=95n=21Age at SLE diagnosis, years18.3 (16)19.2 (15)16 (16)0.32Sex, female93 (80.2)75 (78.9)18 (85.7)0.48Age at kidney biopsy, years21 (17.7)22 (17)18 (15)0.19Patients newly diagnosed SLE with renal biopsy65 (56)53 (55.8)12 (57.1)0.91Follow-up time for LN, years5.5 (8)5.1 (8.2)6.2 (5.1)0.80SLE disease duration8 (8.7)8.1 (9.6)7.9 (7.3)0.53Hypertension31 (26.7)26 (27.4)5 (23.8)0.74Laboratory values on the kidney biopsy Creatinine level (mg/dL)0.7 (0.5)0.8 (0.5)0.56 (0.1)0.006 Creatinine > UNL37 (32.5)34 (36.6)3 (14.3)0.04 eGFR (mL/min/1.73m2)113 (54)107 (54)129 (45)0.04 Albumin (g/dL)3.3 (1.1)3.1 (1.2)3.5 (1)0.09 24-hour urine protein, gr/day2.3 (3.3)2.4 (3.6)0.9 (1.8)0.03 Anti-dsDNA positivity94 (81)80 (87.9)14 (70)0.04 Low C3 and C4 levels93 (80.2)81 (88)12 (57.1)0.001 Active urinary sediment91 (83.5)78 (89.8)12 (57.1)Renal SLEDAI12 (8)12 (8)4 (4)During the two-year follow-up after LN diagnosis Complete renal response70 (70.7)56 (70.9)14 (70)0.99 Partial renal response23 (23.2)17 (21.5)6 (30)0.64 No response6 (6.1)6 (7.6)0NA Relapse20 (21.5)15 (20.5)5 (25)0.84 ESRD4(4)4 (4.2)0NA Death3 (3)3 (3.2)0NA* n (%), if otherwise specified; median (IQR) for numeric valuesESRD: End-stage renal disease, GFR: Glomerular filtration rate, LN: Lupus nephritis, SLE: Systemic lupus erythematosus, SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; UNL: Upper normal limitFigure 1.Kaplan-Meier survival curve for complete renal response (CRR) achievement during the two-year follow-up according to the kidney biopsy resultsDisclosure of InterestsNone declared
- Published
- 2022
28. AB0774 Paradoxical reactions, especially psoriasis in rheumatology patients receiving biologic therapy from the Treasure database: a 5-year follow-up study
- Author
-
B. Yağiz, N. Lermi, B. N. Coşkun, E. Dalkiliç, S. Kiraz, A. İ. Ertenli, E. Bilgin, R. Yilmaz, A. Ateş, A. Tufan, R. Mercan, H. Cinakli, S. Akar, T. Kaşifoğlu, S. M. Türk, E. Gönüllü, A. Erden, C. Bes, H. Emmungil, U. Kalyoncu, and Y. Pehlivan
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundBiologic agents have altered our ability to treat chronic inflammatory diseases effectively. Although paradoxical reactions (PRs) were initially described with TNF-α inhibitors, they have been reported with newly developed biologic agents or classes too (1). Due to the potential consequences of PRs, it is critical to identify and treat these drug class side effects as soon as possible.ObjectivesThe aim of this study was to characterize PRs, especially psoriasis, in a large cohort of patients treated with biologic agents and to investigate their clinical implications.MethodsTReasure database, which was launched in 2017, is a web-based prospective observational cohort comprised of patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) from 17 centers located throughout Turkey. Characteristics of patients with PRs and clinicians’ treatment approaches and outcomes were evaluated using descriptive statistics.Results3147 RA and 6071 SpA patients were evaluated. 139 (1.5%) patients (40 (28.8%) with RA and 99 (71.29%) with SpA) developed a PRs (Table 1). The rate of paradoxical psoriasis was 90.6% and 9.7% of the patients had a family history of psoriasis. Females constituted 64% of the patients. The mean age was 46±12 years and the disease duration were 146±92 months. Mean time interval between the PRs and diagnosis was 99,6±86 months, whereas median 12 (1-132) months between the PRs and the biological agent. Adalimumab (30.9 %), etanercept (20.1 %), and infliximab (18.7 %) were the three most frequently used agents during the PRs. However, 8.6% of the patients developed PRs with non-TNF agents. Only seven patients (5.1%) who had PRs discontinued the drug, while 28 patients (20.6%) continued to receive the agent that caused the PRs. Majority of patients were switched to other TNF-α inhibitors (48.5%) and non-TNF agents (25.7%). When we limited our analysis to paradoxical psoriasis patients, we observed complete remission in 43.5% of patients and progression in only six (4.7 %) of patients. (Figure 1).Table 1.Characteristics of RA and SpA patients who developed paradoxical reactionsNPatients (N, %)Paradoxical reactions (PRs)139 Psoriasis126 (90.6%) Uveitis6 (4.3%) Sarcoidosis2 (1.4%) IBD1 (0.7%) Other*4 (4.3%)Primary disease139 RA40 (28.8%) SpA99 (71.29%)Time interval between PRs-diagnosis of RA/SpA (months)12499,6±86† 72 (3-420) ††Time interval between PRs-biological onset (months)12622±25† 12 (1-132) ††BMI, kg/m212328±5† 27,8 (17,3-49,7) ††Smokers (Current/ex)13161 (46.6%) / 10 (8.5%)Biological agents used during PRs139 TNF-α inhibitor used**127 (91.3%) Secukinumab2 (1.4%) Abatacept6 (4.3%) Rituximab4 (2.9%)Biological agents used after PRs101 Etanercept31 (22.8%) Adalimumab15 (11%) Secukinumab12 (8.8%) Other***43 (57.5%)PRs: Paradoxical reactions IBD: Inflammatory bowel disease. *Drug-induced lupus:3 Vasculitis:1. ** Adalimumab: 43 (30.9%), Etanercept: 28 (20.1%), Infliximab: 26 (18.7%), Certolizumab: 20 (14.4%), Golimumab: 10 (7.2%). *** Certolizumab: 9 (6.6%), Tofacitinib: 9 (6.6%), Infliximab: 7 (5.1%), Tocilizumab: 5 (3.7%), Golimumab: 4 (2.9%), Ustekinumab: 4 (2.9%), Rituximab:3 (2.2%), Abatacept: 1 (0.7%), Anakinra: 1 (0.7%). † mean ± standard deviation. †† median (min-max)ConclusionClinicians should be aware that PRs may develop with biologic agents other than TNF-α inhibitors. Additionally, it is important to keep in mind that the development time of PRs could be variable. The mechanism(s) behind PRs remain unknown, and there is no currently available diagnostic or therapeutic protocol (2). The decision whether to continue or discontinue biologic agents should be individualized. We found that the majority of patients can be managed without discontinuing biologic agents. Finally, we believe that the experience of our large cohort can help physicians in clinical practice where sufficient protocol is lacking.References[1]Lluís Puig. Curr Probl Dermatol. 2018; 53:49-63.[2]Michael J Murphy. J Am Acad Dermatol. S0190-9622(20)33154-6.Disclosure of InterestsNone declared
- Published
- 2022
29. AB0912 Swollen and tender joints improvement in the randomized controlled trials of psoriatic arthritis
- Author
-
M. Ekici, E. Unaldi, G. Ayan, E. Bilgin, and U. Kalyoncu
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundThe ACR response is used to evaluate peripheral joints in psoriatic arthritis. However the main component in ACR treatment response is swollen (SJ) and tender joints (TJ), therewithal patient and physician global assessment, acute phase response, pain and function are included in this treatment response. Therefore, it can be thought that peripheral arthritis can best evaluated over SJ and TJ. Although ACR treatment responses are generally found to be similar between anti-TNF and anti-IL17/anti-IL23 in PsA, there is a general opinion that anti-TNF treatments may be more effective on the peripheral joint. (1).ObjectivesIn this study, it was aimed to evaluate the efficacy on SJ and TJ in RCTs performed in PsA.MethodsWe was searched with the keywords ‘psoriatric arthritis’ and ‘randomized controlled trial’ in Pubmed. All studies between 1975 and 31.10.2021 were screened for TJ count (SD) and SJ count (SD) values at treatment initiation and primary endpoint. The 2 studies with anti-TNFs and the SPIRIT-1 study comparing ixekizumab with placebo and adalimumab showed the number of SJ and TJ at baseline and primary endpoint. Effect size calculated separately according to Morris and Klauer formula. (2,3) We can interpret the effect size according to Cohen as follows: 0-0,1 no effect; 0,2-0,4 small effect; 0,5-0,7 intermediate effect; 0,8-≥1 large effect. (4)ResultsCertolizumab study, ES was found at a good level in the number of TJ and SJ at 200 and 400 mg doses. (ES 0.84 for SJ). The study comparing ixekizumab with adalimumab and placebo, it was observed that administration of ixekizumab every 4 weeks was minimally more effective in the number of TJ (ES 0.16) and SJ (ES 0.13) than adalimumab. The effect of ixekizumab over placebo is also slightly better than that of Adalimumab over placebo. (0.51 vs 0.36 in TJ, 0.38 vs 0.29 in SJ)Table 1.Effect size analysis of studiesTender Joint CountReferenceWeek (w)InterventionControlBaseline (Intervention vs Control)ES (Morris)ES (Klauer)Spirit-112Ixekizumab 4 w (n=107)Adalimumab (n=101)20,5 (13,7) vs 19,3 (13,0)0.160.9112Ixekizumab 2 w (n=103)Adalimumab (n=101)21,5 (14,1) vs 19,3 (13,0)0.120.2912Ixekizumab 4 w (n=107)Plasebo (n=106)20,5 (13,7) vs 19,2 (13,0)0.515.112Ixekizumab 2 w (n=103)Plasebo (n=106)21,5 (14,1) vs 19,2 (13,0)0.473.912Adalimumab (n=101)Plasebo (n=106)19,3 (13,0) vs 19,2 (13,0)0.364.1GENOVESE, Mark C., et al. M02-570 Study Group12Adalimumab (n=51)Plasebo (n=49)25,3 (18,3) vs 29,3 (18,1)0.190.30RAPID-PsA24Certolizumab 200 mg (n=138)Plasebo (n=136)21,5 (15,3) vs 19,9 (14,7)0.670.7524Certolizumab 400 mg (n=135)Plasebo (n=136)19,6 (14,8) vs 19,9 (14,7)0.490.61Swollen Joint CountSpirit-112Ixekizumab 4 w (n=107)Adalimumab (n=101)11.4 (8.2) vs 9.9 (6.5)0.130.6312Ixekizumab 2 w (n=103)Adalimumab (n=101)12,1 (7,2) vs 9,9 (4,7)0.191.1812Ixekizumab 4 w (n=107)Plasebo (n=106)11,4 (8,2) vs 10,6 (7,3)0.383.812Ixekizumab 2 w (n=103)Plasebo (n=106)12,1 (7,2) vs 10,6 (7,3)0.453.212Adalimumab (n=101)Plasebo (n=106)9.9 (6.5) vs 10.6 (7.3)0.294.4GENOVESE, Mark C., et al. M02-570 Study Group12Adalimumab (n=51)Plasebo (n=49)18.2 (10.9) vs 18.4 (12.1)0.330.29RAPID-PsA24Certolizumab 200 mg (n=138)Plasebo (n=136)11.0 (8.8) vs 11.0 (8.8)0.840.8324Certolizumab 400 mg (n=135)Plasebo (n=136)10.5 (7.5) vs 11.0 (8.8)0.840.87ConclusionChanges in the number of SJ and TJ that directly assess the peripheral joint have not been reported enough in RCTs in PsA patients. According to a limited number of reports, Anti-TNFs (eg, certolizumab) cause significant improvement in the number of SJ and TJ in the primary endpoint. On the other hand, Ixekizumab has as much effect on SJ and TJ as Adalimumab. The effect of anti-IL 17 treatments on the peripheral joint is not less than that of anti-TNFs, as thought.References[1]Noviani M et at. Ther Adv Musculoskelet Dis. 2020[2]Klauer, K. J. Handbuch kognitives Training[3]Morris, S. B. Estimating Effect Sizes From Pretest-Posttest-Control Group Designs.[4]Cohen, J. Statistical power analysis for the behavioral sciences (2. Auflage)Disclosure of InterestsNone declared
- Published
- 2022
30. AB0282 COMORBIDITIES ARE MORE IMPORTANT THAN JAK INHIBITORS: VENOUS THROMBOEMBOLISM IN RHEUMATOID ARTHRITIS
- Author
-
G. Sandal Uzun, M. Bahap, O. Yucel, Y. Kaygusuz, E. Bilgin, L. Kiliç, A. Akdoğan, O. Karadag, Ş. A. Bilgen, S. Kiraz, A. İ. Ertenli, and U. Kalyoncu
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundThe risk of Venous thromboembolisim (VTE) is increased and is an important cause of mortality and morbidity in rheumatoid arthritis. In addition to the underlying Rheumatoid arthritis(RA), there are a number of predisposing risk factors for VTE(1).ObjectivesIn this study, we aimed to evaluate the demographic and clinical features of rheumatoid arthritis patients with VTE.MethodsPatients who were refered to Hacettepe University Medical Rheumatology department from January 2021 to December 2021 retrospectively analyzed. A total 981 RA patients were detected according to the ICD code(M05, M06, MO07). RA diagnosis was confirmed in 400 patients according to 2010 ACR/EULAR criteria. Venous thrombosis was confirmed by ICD code(I26,I74,I82), computed torax tomography, lower extremity venous doppler and medical treatment report in these 400 patients with RA. Thromboembolism was detected in 58 patients during follow-up. The patients’ clinical characteristics, serological features, co-morbidities, and treatment were systematically analysed.ResultsVTE was diagnosed in 58 patients with RA. Of these patients, 84,5% was female and mean (SD) age was 67.5 ± 11,1 years. The majority of patients had deep venous thrombosis (53.4%). Rate of rheumatoid factor and/or anti-cyclic citrullinated peptid positivity was 72.5% and ANA positivity was 68% respectively. Distribution of cDMARDs and bDMARDs before VTE was as follows: methotrexate 18 (45%), leflunomide (35%), sulfasalazine (22.5%), hydroxychloroquine (47.5%), steroid (47.5%), biological agents (22.5%). Comorbidities were common and The Charlson Comorbidity Index score was ≥3 in 89.6% of patients with VTE. VTE frequency of patients in the last 1 year was %1.27.ConclusionAll RA patients with VTE had at least one comorbidity and 89% of patients had multi-morbidities. RA patients with multimorbidity may have an increasded risk of VTE. In the management of RA, comorbidities should be taken into account.References[1]Ketfic, Boutigny A, et al. Risk of venous thromboembolisim in rheumatoid arthritis Joint Bone Spine 2021 May;88(3) 105122Table 1.Demographic, Clinic and treatment Features of venous thromboembolisim with RADemographic, Clinic and treatment FeaturesVTE in RA patients N=58(%)Age, years, mean(SD)67,5 (±11.1)Female, n(%)49(84.5)Charlson Comorbidity Index score(CCI) ○ CCI12(3.4) ○ CCI24(6.8) ○ CCI3 and higher52(89.6)Smoking, ever, n(%)20 (41.6)Presentation of Venous thromboembolism ○ deep vein thrombosis, n(%)27(46.6) ○ pulmonary thromboembolism, n(%)26(44.8) ○ DVT+PTE, n(%)5(8.6)Treatment before venous thrombosis, n(%) ○ Methotrexat18(45) ○ Leflunomid14(35)◦ ○ Sulfasalazin9(22.5) • Hydroxychloroquine19(47.5) • Biologic agents9(22.5) • Steroid19(47.5)Treatment, ever, n(%) • Methotrexat (n=44)39(88.6) • Leflunomid(n=42)24(52.1) • Sulfasalazin(n=47)29(62) • Hydroxiclorokine(n=49)44(89) • Steroid(n=54)50(92.5) • Tofacitinip19(34.5) • Biologic agents2(0.03) ○ Abatacept3(0.05) ○ Adalimumab5(0.09) ○ Etanercept3(0.05) ○ Rituximab9(16) ○ Certolizumab1(0.01) ○ İnfliximab1(0.01)Comorbidity, n(%)35(60.3)10(17.2)40(70.2)11(19)8(13.8)8(13.8)15(30.6)5(8.6)7(12.5) 10(25.6)8(13.8) 54(93.1)CRP/mg/dl at venous thrombosis, mean, (SD)0.98(±5.2)Erytrochyte Sedimentation rate/mmhour at venous thrombosis, mean,(SD)25 (±22.3)Seropositive, n(%)41 (73.2%)ANA positive, n(%)34 (68%)Disclosure of InterestsNone declared
- Published
- 2022
31. AB0940 Is psoriatic arthritis really seronegative?
- Author
-
G. Ayan, N. E. Gezerer, E. Bilgin, G. K. Yardimci, E. C. Bolek, B. Farisogullari, E. Duran, Z. Özsoy, G. Sandal Uzun, M. Ekici, E. Unaldi, L. Kiliç, A. Akdogan, O. Karadag, Ş. A. Bilgen, S. Kiraz, A. İ. Ertenli, and U. Kalyoncu
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundPsoriatic Arthritis (PsA) is a heterogeneous disease classified as a seronegative group of inflammatory arthritis.ObjectivesOur aim was to understand the real-life seropositivity rates for commonly used autoantibodies in rheumatology practice in a cohort of PsA patients treated with biologic agents.MethodsPsA patients from the Hacettepe University biological database (HUR-BIO) were assessed for the anti-nuclear antibody (ANA), rheumatoid factor (RF), and anti-cyclic citrullinated peptide (CCP) before and after the initiation of biologic agents. Demographic characteristics, the interval between the test and biologic initiation, and the rates of seropositivity for individual tests, autoantibody titers, and subtypes for ANA were determined.ResultsFrom 520 PsA patients registered, results of 419 patients with at least one autoantibody tested either before or after biologic treatment is presented in Table 1. From the patients tested, 69% of them had at least one autoantibody positive and 30.8 % of them were triple negative before the biologic treatment. The rates reached to 78.7% of seropositivity for at least one autoantibody and 21.2 %triple negativity after treatment. ANA showed the highest rates of seropositivity among autoantibodies with a rate of 40% before and 55.3 % after biologic treatment. Concomitant seropositivity for RF and CCP autoantibodies showed rates of 2.8% and 6.3% before and after treatment, respectively. The most common subtype was AC4-5 before and AC1-4-5 after biologic agent treatment. ANA was tested in 31 patients both before and after biologic treatment showing 6 negative patients became positive after treatment and from 12 positive patients at the baseline 6 of them became negative (p=0.452). The most common biologic agents used in patients with ANA tested after treatment, were adalimumab (ADA) (42.4%), etanercept (ETN) (18.9%), and infliximab (IFX) (18.9%). The only difference was observed in IFX treated patients (n=25) with significantly higher rates of IFX usage in ANA-positive patients (p=0.001).Table 1.Demographics and ANA, RF, Anti-CCP test results of patients before and after biologic treatmentANARFAnti-CCPbDMARDs initiationBeforeAfterBeforeAfterBeforeAfterNumber of patients10413231027814497Age43.5 (12.7)46.7 (11.6)43.3 (12.5)47.9 (11.9)44.3 (12)48.6 (12.1)Female sex, n (%)84 (80.7)97 (73.5)225 (72.5)211 (75.8)110 (76.3)75 (77.3)Time interval between test and bDMARD initiation, months, median (IQR)7.4 (0.84-17.83)32.6 (14.93-72.33)4.1 (0.35-16.75)31.63 (13.10-64.08)3.23 (0.30-11.5)35.13 (12.40-75.43)Positivity, n (%)42 (40.4)73 (55.3)30 (9.6)32 (11.5)12 (8.3)11 (11.3)Titer IU/ml, median (IQR)NANA28.7 (22.35-98.5)28.9 (21.9-110)139.1 (20.38-250)67.5 (16.77-139)Titer, n (%) *28 (66.6)38 (52)N/AN/AN/AN/A1/1007 (16.7)14 (19.1)1/1607 (16.7)20 (27.3)≥1/320bDMARD: Biologic Disease Modifying Anti-Rheumatic Drugs, ANA: Anti-nuclear antibody, RF: Rheumatoid factor, Anti-CCP: Anti- Cyclic citrullinated peptide, F:Female, M:Male, IQR: Interquartile range, IU/ml: International units per milliliter, N/A: Not available*Subtype is not given for one patient in patients with positive ANA after biologic treatmentConclusionSynovial lymphoid neogenesis rates in PsA are similar to the frequency seen in rheumatoid arthritis (1). Nevertheless, PsA is classified under the group of “seronegative diseases”. On the other hand, current reports have started to define specific autoantibodies particularly in psoriasis patients (2). The real-life experience in serology results of PsA patients showed that only 20-30 % of the patients were seronegative for all three tests commonly used in practice.References[1]Celis R, et al. Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther. 2012 Apr 27;14(2):R93.[2]Yuan Y, et al. Identification of Novel Autoantibodies Associated With Psoriatic Arthritis. Arthritis Rheumatol. 2019 Jun;71(6):941-951.Disclosure of InterestsNone declared
- Published
- 2022
32. POS0991 PREDICTORS OF DEVELOPMENT OF ADVANCED SPINAL ANKYLOSIS/BAMBOO SPINE IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM REAL-LIFE DATA
- Author
-
B. Farisogullari, G. K. Yardimci, E. Bilgin, E. C. Bolek, E. Duran, G. Ayan, Z. Özsoy, G. Sandal Uzun, M. Ekici, E. Unaldi, L. Kiliç, A. Akdoğan, O. Karadag, Ş. A. Bilgen, S. Kiraz, U. Kalyoncu, and A. İ. Ertenli
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundIn axial spondyloarthritis (axSpA), intervertebral ossification bridges of consecutive vertebrae may progress to advanced spinal ankylosis and bamboo spine over the years [1].ObjectivesTo identify demographic, clinical, disease activity and treatment factors associated with development of bamboo spine / advanced spinal ankylosis and bamboo spine-only in the Hacettepe University Rheumatology Biologic Registry (HUR-BIO) cohort.MethodsHUR-BIO is a prospective, single center database of biological disease-modifying antirheumatic drug (bDMARD) treatments. 770 patients on bDMARDs treatment had both lumbar and cervical lateral radiographies at the time of the data collection, and were included in the study. Bamboo spine was defined Bath Ankylosing Spondylitis Radiologic Index (BASRI)-spine grade 4 with a complete fusion of lumbar and cervical spines. Advanced spinal ankylosis was defined as the presence of at least two intervertebral adjacent bridges and/or fusion at the lumbar and/or cervical spine without bamboo spine. We analyzed the ensemble of variables by multivariable logistic regression to identify predictors associated with bamboo spine / advanced spinal disease, and bamboo spine-only.ResultsIn the study, there were 99 patients with advanced spinal ankylosis and 78 patients with bamboo spine. Older age (OR 1.12, 95% CI 1.07-1.17), male gender (OR 4.26, 95% CI 1.75-10.41), delay diagnosis ≥ 24 months (OR 2.7, 95% CI 1.27-5.74), obesity (OR 4.03, 95% CI 1.53-10.64), hip involvement (OR 4.94, 95% CI 1.94-12.6), smoking ≥ 10 package/year (OR 2.28, 95% CI 1.003-5.2) were significantly associated factors with bamboo spine / advanced spinal ankylosis. Similarly, older age (OR 1.17, 95% CI 1.09-1.3), male gender (OR 8.31, 95% CI 2.09-33.1), obesity (OR 5.15, 95% CI 1.25-21.27), hip involvement (OR 4.74, 95% CI 1.32-16.96) and smoking ≥ 10 package/year (OR 3.19, 95% CI 1.03-9.89) were showed statistical significance with bamboo spine (Table 1).Table 1.Predictors of Bamboo Spine and Advanced Spinal Ankyloses, and Bamboo Spine-onlyMultivariable ModelCovariatesBamboo Spine and Advanced Spinal AnkylosisBamboo SpineOR (95% CI)p-valueOR (95% CI)p-valueAge1.12 (1.07-1.17)1.17 (1.09-1.3)Male (vs female)4.26 (1.75-10.41)0.001*8.31 (2.09-33.1)0.003*Delay Diagnosis (≥ 24 months vs )2.7 (1.27-5.74)0.01*2.39 (0.85-6.71)0.09BMI0.019*0.074- 25 to < 30 (vs )2.05 (0.77-5.46)0.153.37 (0.84-13.6)0.087- ≥ 30 (vs )4.03 (1.53-10.64)0.005*5.15 (1.25-21.27)0.024*Hip involvement (present vs absent)4.94 (1.94-12.6)0.001*4.74 (1.32-16.96)0.017Smoking (≥ 10 package/year vs )2.28 (1.003-5.2)0.049*3.19 (1.03-9.89)0.044*Family History of SpA (First-degree; present vs absent)1.67 (0.61-4.57)0.322.82 (0.79-10.06)0.11Uveitis History (present vs absent)1.04 (0.39-2.74)0.941.19 (0.33-4.29)0.79Use SSZ (present vs absent)0.6 (0.17-2.07)0.422.09 (0.39-11.28)0.39Use Corticosteroids (present vs absent)0.69 (0.27-1.75)0.430.73 (0.18-2.97)0.66*p BMI: Body mass index; SpA: Spondyloarthritis; SSZ: SulfasalazineConclusionData on the predictors of development of advanced spinal ankylosis and bamboo spine are scarce. In this study, we showed that older age, male gender, delay in diagnosis, obesity, hip involvement and smoking are factors that predict the development of advanced spinal involvement in axSpA.References[1]Ostergaard M, Lambert RG. Imaging in ankylosing spondylitis. Ther Adv Musculoskelet Dis. 2012;4(4):301-11.Disclosure of InterestsNone declared
- Published
- 2022
33. POS1187 DO IMMUNOSUPPRESSIVE AGENTS AFFECT IGRA TESTS IN PATIENTS WITH RHEUMATOID ARTHRITIS?
- Author
-
Z. Özsoy, A. Özdemir, M. Ekici, E. Bilgin, L. Kiliç, S. Kiraz, Z. Saribaş, B. Şener, and O. Karadag
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundTuberculin skin test (PPD) or interferon gamma release assays (IGRAs) are used to detect latent tuberculosis infection. Induration of 15 mm or more is considered positive in any person whereas this cut-off is ≥5 mm for immunosuppressed individuals such as Rheumatoid arthritis. Since IGRAs are dependent on normal T-cell function, it may result in false-negatives for among RA patients due to disease itself and immunosuppressive drugs.ObjectivesWe aimed to compare IGRA results of RA patients using high dose DMARDS vs. not using any of them.MethodsTotally 534 RA patients among Hacettepe University Rheumatology Biologic Registry Database (HURBIO) database was enrolled into this study. QFT-Plus test of patients with rheumatoid arthritis (RA) between January 2018 and March 2021 during work up before biologic/targeted therapy were analysed, retrospectively. The patient group was divided into two according to the drugs have been using at the time of IGRA test. Patients using methotrexate ≥ 10 mg or leflunomide (any dose) or steroids (≥7.5 mg prednisolone) or any combination thereof were classified as the “High Dose” group. The other group consisted of patients who did not take these drug doses. Demographic characteristics, comorbidities, drugs and doses used, and hemogram, sedimentation, and CRP values of the patients were recorded. QuantiFERON test was recorded as positive, negative, indeterminate.Results353(66.1%) RA patients were in the high dose patient group and also 287(81.3%) of these patients were female, the median age was 55 years (min:19- max:82). The high dose group was older than the other group. When the two groups were compared, no statistically significant difference was found between comorbidity, and smoking (Table 1). While QFT positivity was detected in 37 (10.5%) patients in the high-dose group, it was found to be positive in 37 (20.4%) patients in the other group (pTable 1.Comparison of RA patients’ groups using high-dose immunosuppressives and not using any of themHigh Dose Methotrexate or Leflunomide or Steroid (+), (%)66.1High Dose Methotrexate or Leflunomide or Steroid (-), (%)33.9P ValueFemale81.375.10.09Age, med (min-max)55 (19-82)52 (19-81)0.01Diabetes Mellitus1110.50.84Hypertension30.624.90.16Chronic Renal Failure0.300.66Chronic Obstructive Pulmonary Disease4.23.30.59Coronary Artery Disease3.76.10.20History of malignancy0.81.70.40SmokingNever4952.50.19Ever24.127.6Quit26.318.8Leukocyte,*103/mlMedian (min-max)7.6 (2.8-28.8)7.9 (3.5 – 20.8)0.26Neutrophil,*103/ml4.8 (0.2-23.0)5.0 (1.5-19.1)0.18Lymphocyte,*103/ml1.9 (0.4-5.9)1.8 (0.5-5.3)0.67Thrombocyte,*103/ml285 (117-669)285.5 (60-724)0.79Hemoglobine,g/dL12.8 (7.7-17.9)12.8 (9.3-16.6)0.41Sedimentation,mm/saat30 (2-294)28 (2-104)0.27C Reactive Protein,mg/dl1.1 (0.1-62.8)1.1 (0-20.7)0.96QuantiFERON-TB Gold-Plus (QFT-Plus)10.520.40.00Nil med (min-max)0.07 (0-2.7)0.05 (0-0.85)0.48QFT-Plus TB-1 med (min-max)1 (0->10)0.99 (0->10)0.25QFT-Plus TB-2 med (min-max)1 (0->10)1.1 (0->10)0.42Mitogen med (min-max)10 (0->10)9.5 (0->10)0.27MethotrexateNot Taking31.433.7Less than 10 mg44.266.310 mg and more24.40LeflunomideNot Taking25.8100Taking74.20HydroxychloroquineNot Taking25.240.9Taking74.859.1SulfasalazineNot Taking62.661.9Taking37.438.1SteroidsNot Taking4.219.9Less than 7.5 mg66.380.17.5 mg and more29.50ConclusionOur results confirmed a significantly lower QFT-Plus positivity in patients with RA taking methotrexate ≥ 10 mg or leflunomide (any dose) or steroids (≥7.5 mg prednisolone). Physicians should be careful in interpretation of QFT-Plus in patients with rheumatoid arthritis. Further analysis including flow cytometry analysis is required to better identifying cut-offs for immunosuppressive individuals and patients with inflammatory rheumatic diseases.Disclosure of InterestsNone declared
- Published
- 2022
34. POS0601 CRANIOCERVICAL JUNCTION INVOLVEMENT ASSESSED BY COMPUTED TOMOGRAPHY AND/OR MAGNETIC RESONANCE IMAGING IN INFLAMMATORY ARTHRITIS: SINGLE CENTER CASE-CONTROL STUDY
- Author
-
F. Yalçinkaya, Ş. Parlak, E. Bilgin, K. Karli Oğuz, and U. Kalyoncu
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundCraniocervical involvement is generally overlooked clinically.ObjectivesThe aim of this study is to investigate the craniocervical involvement in inflammatory arthritidies and compare with patients without inflammatory arthritidies.MethodsIn this retrospective analysis, cervical CT and/or MRI scans -taken for any reasons between 2010 and 2020 - of patients with rheumatoid arthritis (RA), spondyloarthritis (SpA) and psoriatic arthritis (PsA) (M05, M06, M07 and M45) according to ICD-10 codes were scanned from the hospital database. The diagnosis of RA, AS, and PsA was confirmed by an experienced clinician with medical history, laboratory, and treatment history. Of these patients, those who underwent CT and/or MRI before the definitive diagnosis of inflammatory arthritis were included in the analyses. Demographic data of the included patients were recorded. Craniocervical involvements (anterior, posterior, lateral, and rotational atlantoaxial subluxation; vertical subluxation; subaxial subluxation; odontoid process involvement [resorption or pannus], atlantoaxial and atlantooccipital involvement) were evaluated by an experienced radiologist on CT or MRI, as appropriate. Control group was consisted of consequent patients without inflammatory arthritidies and who undergone cervical CT or MRI with any reasons out of trauma. pResultsFrom a total of 4442 records (1558 individual patients), 459 patients (204 RA, 200 SpA, and 55 PsA patients) and 78 patients for control group were included in the study. In Table 1, comparison of RA, SpA and control groups was given. The percentage of female gender and age at diagnosis were lower in SpA patients. Craniocervical junction involvement was detected in 101 (49.5%) RA, 53 (26.5%) SpA, 4 (5.1%) of control group, pTable 1.Comparison of RA, SpA and control groups for spesific types of craniocervical involvementsConclusionCraniocervical junction involvement can often be detected in patients with inflammatory arthritis, especially in patients with RA. Odontoid process seems as the main target of inflammation. Craniocervical involvement has the potential to be overlooked clinically, and needs to be evaluated more carefully.Disclosure of InterestsNone declared
- Published
- 2022
35. AB0275 THE FREQUENCY, PREVALENCE OF CORONARY ARTERY DISEASE AND PRE-MATURE CAD IN PsA AND RA PATIENTS
- Author
-
G. Ayan, G. Sandal Uzun, O. D. Tatar, N. E. Gezerer, E. Bilgin, G. K. Yardimci, E. C. Bolek, B. Farisogullari, E. Duran, Z. Özsoy, M. Ekici, E. Unaldi, L. Kiliç, A. Akdogan, O. Karadag, Ş. A. Bilgen, S. Kiraz, A. İ. Ertenli, and U. Kalyoncu
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundAn increased incidence of coronary artery disease (CAD) is known in inflammatory arthritis patients compared to the normal population. In the Veterans With Premature Atherosclerosis (VITAL) registry, the frequency of premature CAD (CAD < 55 in men, < 65 years in women) in autoimmune rheumatic diseases was 1.72 (95% CI 1.63-1.81) in Rheumatoid arthritis (RA) compared to the healthy population in approximately 135,000 patients, while a similar situation was not observed in Psoriatic arthritis (PsA) patients 1.09 (95%CI 0.98-1.21) (1).ObjectivesIn this study, we aimed to compare the frequency of CAD and premature CAD in RA and PsA patients using bDMARDs.MethodsThe Hacettepe University biological database (HUR-BIO), database was established in 2005 and prospective follow-up of patients using bDMARDs is being carried out. The frequency of CAD was recorded in 486 PsA and 524 RA patients using bDMARDs. CAD was determined according to the angiography reports or Coronary Computed-Tomography results. Premature CAD is defined as a history of CAD before the age of 55 in men and before the age of 65 in women. Demographic characteristics and other comorbid conditions of the patients were also noted. Disease activity (DAS-28) and functional status (HAQ-DI) of the patients before the first DMARD initiation were recorded.Results581 (75.4% female) RA and 520 (69.4% female) PsA patients were evaluated. The ages of the patients and the duration of the disease are as follows; RA, mean (SD) years of age 52.1 (13.9), disease duration 5.3 (2.1) years, PsA mean (SD) years of age 48.7 (12.5), disease duration 9.2 (6.4). At the time of first bDMARD initiation, 43/581 (7.4%) patients with RA and 12/486 (2.4%) patients with PsA had CAD (p
30, n(%)19 (52.3)7 (35.0)0.208 (44.4)11 (78.5)0.051HT (ever), n(%)23 (63.9)14 (66.7)0.8911 (61.1)13 (92.8)0.040DM (ever), n(%)20 (57.1)9 (52.9)0.774 (22.2)6 (42.8)0.45LDL > 130 (ever), n(%)29120.1311 (61.1)5 (35.7)0.14DAS-284.7 (1.1)4.2 (1.2)0.114.7 (1.4)4.5 (1.5)0.72HAQ (0-3)1.41 (0.7)1.05 (0.8)0.0790.7 (0.6)1. 3 (0.7)0.13RA: Rheumatoid arthritis, PsA: Psoriatic arthritis, CAD; Coronary artery disease, BMI; Body-mass index, HT: Hypertension, DM: Diabetes mellitusConclusionWhile the frequency of premature CAD is 10% in the normal population, CAD has a premature character in two-thirds of RA patients and 55% of PsA patients (2). In a large community-based study, the frequency of premature CAD was found to be increased in RA patients compared to the normal population, but no similar difference was observed in PsA patients (1). In real-life data in which we examined a large group of patients using bDMARDs, it is seen that the subtype of CAD is of pre-mature character in both RA patients and PsA patients.References[1]Mahtta D et al. Am J Med. 2020 Dec;133(12):1424-1432[2]Cole JH, et al. Curr Atheroscler Rep. 2004 Mar;6(2):121-5.Disclosure of InterestsNone declared
- Published
- 2022
36. AB0766 Biologic Drug Preferences of Turkish Rheumatologists in Spondiloartropathy Patients with Advanced Chronic Renal Disease
- Author
-
R. Mercan, M. E. Tezcan, B. Yağiz, A. Ateş, O. Küçükşahin, N. S. Yasar Bilge, N. A. Kanitez, E. Gönüllü, S. Yilmaz, D. Ersözlü, D. Solmaz, T. Kaşifoğlu, B. N. Coşkun, S. S. Koca, E. Bilgin, V. Yazisiz, E. Dalkiliç, R. Yilmaz, G. Kimyon, G. Ayan, A. Erden, C. Bes, H. Emmungil, Y. Pehlivan, A. İ. Ertenli, S. Kiraz, and U. Kalyoncu
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundBiological therapies are the main treatment options for patients with active spondyloarthropathy (SpA) who do not respond to nonsteroidal anti-inflammatory drugs or conventional synthetic disease-modifying drugs. Kidney diseases are not a contraindication to biologic therapies. However, there are some safety concerns for these drugs for patients with advanced chronic kidney disease. De novo infection or recurrence of infections are the main challenges in patients with multiple comorbidities during biologic treatments. Neverthless, physicans should initiate these treatments in active and resistant diseases.ObjectivesHere, we evaluated which biologic therapies clinicians’ first option to initiate in SpA patients with advanced chronic kidney disease (CRD).MethodsTotal 140 patients of TREASURE database who fullfield axial and/or peripheral ASAS SpA criteria with glomerular filtration rate < 60 ml/dk (stage 3,4 or 5 CRD according to The National Kidney Foundation classification) were included to the study. Renal stages of the patients were evaluated when biologic therapy was initiated. Five anti-TNF (adalimumab, certolizumab, etanercept, golimumab, infliximab) and an interleukin-17A blocker (secukinumab) were on the market during the study. We evaluated physicans’ first choice for biologic therapy for patients with stage 3,4 and 5 CRD respectively.ResultsMore than two thirds of the patients had stage 3 CRD. Anti-TNF drugs were the first choice of biologic treatment in the patients with advanced CRD. Etanercept was started at most to the patients in general, in stage 3 and in stage 5 CRD groups. However, adalimumab was the first choise in stage 4 CRD. Both etanercept and adalimumab were the first drug of choise in three fourth of the stage 4 and stage 5 patients. All two patients on Il-17A blocker had stage 3 CRD (Table 1).Table 1.Drug of choise in the SpA patients with advanced chronic renal diseasesNTotal n (%)NStage 3 n (%)NStage 4 n (%)NStage 5 n (%)Adalimumab14044 (31.4)10830 (27.8)209 (45.0)125 (41.6)Etanersept52 (37.1)41 (38.0)5 (25.0)6 (50.0)Golimumab9 (6.0)7 (6.5)2 (10.0)0 (0)Infliksimab28 (20.0)23 (21.3)4 (20.0)1 (8.4)Secukinumab3 (2.1)3 (2.8)0 (0)0 (0)Sertolizumab4 (2.8)4 (3.7)0 (0)0 (0)ConclusionWe show that rheumatologists in the TREASURE group prefer to initiate anti-TNF drugs first in all advanced CRD stages. Etanercept was the first choice in these patients.References[1]Sieper J, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009 Jun;68 Suppl 2:ii1-44. doi: 10.1136/ard.2008.104018. PMID: 19433414.[2]Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S152-7. PMID: 12463468.[3]Kalyoncu U, et al. Methodology of a new inflammatory arthritis registry: TReasure. Turk J Med Sci. 2018 Aug 16;48(4):856-861. doi: 10.3906/sag-1807-200. PMID: 30119164.Disclosure of InterestsNone declared
- Published
- 2022
37. AB0808 Costovertebral, Costotransverse, Sternoclavicular and Manubriosternal Joint Involvement in Spondyloarthritis: Preliminary Results of Single Centre Experience
- Author
-
E. B. Ata, E. Bilgin, G. Durhan, G. Ayan, M. Ariyürek, and U. Kalyoncu
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundCostovertebral (CV), costotransverse (CTr), sternoclavicular (SC) and manubriosternal (MS) joint involvements may be in spondyloarthritis (SpA). However, the radiological and clinical characteristics of these involvements need further assessment.ObjectivesIn this study, we aimed to determine the characteristics of CV, CTr, SC, and MS joint involvements in SpA patients.MethodsSpA patients (searched from the hospital data-processing system according to ICD-10 system to determine the patients having M07 (enteropathic arthropathies), M45 (ankylosing spondylitis (AS)), M46 (other inflammatory spondylopathies) and/or M48 (other spondylopathies) codes) who have been requested a chest computed tomography (CT) for any reason between January 2010 and December 2020 included in this retrospective cross-sectional analysis. Chest CT reports were reviewed, and any CV, CTr, SC or MS joint involvement attributed to SpA accepted as positive CT for SpA involvement. Demographic/clinic data including smoking status, disease characteristics (duration, drug history, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI) and other related parameters) at the time of CT scan were collected and analyzed.ResultsAfter the confirmation of the diagnoses among 1700 patients, total of 339 SpA patients were included in the study. 244 were diagnosed with ankylosing spondylitis (AS), 66 with psoriatic arthritis (PsA), 14 with enteropathic arthritis, 13 with peripheral SpA, and 2 with non-radiographic axial SpA. According to CT reports, the number of patients with inflammatory changes in any of the CV, CTr, SC or MS joints on thoracic CT were 44. Of these patients, 42 were diagnosed with AS (95,5%), 1 with PsA (2,3%), and 1 (2,3%) with peripheral SpA. 39 CV, 9 SC, 5 MS joints, and 3 CTr joints were affected. Joint involvements (17%) were higher in patients with AS than in other patient groups (pTable 1.Demographic and clinical characteristics of patients with and without involvement on chest CTData are presented as median (25-75 percentile) or number (%)CT; computerized tomography, BMI; body mass index, ESR; erythrocyte sedimentation rate, CRP; C-reactive protein, BASDAI; Bath Ankylosing Spondylitis. Disease Activity Index, BASMI; Bath Ankylosing Spondylitis Metrology Index, BASFI; Bath Ankylosing Spondylitis Functional IndexConclusionIn this study, we have found that CV, CTr, SC, and MS joint involvement on thorax CT were more common in men and smokers and were associated with disease duration and appears to affect chest expansion and Schober’s tests. In previous studies, CV and CTr joint involvement in AS patients with chest pain were 80-82% and 60%, respectively [1,2]. Our study showed that 17% of AS patients had involvement regardless of pain symptoms. As this is the preliminary data and the CTs will be re-evaluated by our radiologist, we will be capable to report more unbiased results.References[1]Cerrahoglu L, Unlu Z, Can M, et al. (2002) Lumbar stiffness but not thoracic radiographic changes relate to alteration of lung function tests in ankylosing spondylitis. Clin Rheumatol. 21(4):275-279.[2]Pascual E, Castellano JA, López E. (1992) Costovertebral joint changes in ankylosing spondylitis with thoracic pain. Br J Rheumatol. 31(6):413-415.Disclosure of InterestsNone declared
- Published
- 2022
38. POS0602 PULMONARY RHEUMATOID NODULES: DOES SEROLOGIC STATUS MATTER?
- Author
-
Y. Sarikaya, G. Sandal Uzun, E. B. Ata, S. Arslan, M. Ekici, G. Durhan, E. Bilgin, U. Kalyoncu, and M. Ariyürek
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundThe frequency of pulmonary rheumatoid nodules closely relates to the diagnostic modality and changes from ObjectivesWe aimed to compare the disease and pulmonary rheumatoid nodule characteristics of seropositive and seronegative RA patients.MethodsIn this study, all RA patients - according to ICD-10 code - and had at least one chest computerized tomography (CT) were examined and revealed 4117 individual patients. First, RA diagnosis was confirmed according the patients’ history, physical examination, radiography and laboratory assessment. Then, chest CTs were examined by an experienced radiologist. To classify pulmonary nodules as ‘’pulmonary rheumatoid nodule’’, following inclusion and exclusion criteria were used; For inclusion: 1) nodules with changing dimension on follow-up, 2) At least two nodules with different dimensions, 3) Cavitary nodule at any chest CT. For exclusion: 1) Solitary nodules OR all nodules ≤ 5mm and without follow-up OR no change on follow-up. Biggest nodule was named as dominant nodule. Then, patients were grouped according to rheumatoid factor and anti-CCP status as seropositive (RF ± anti-CCP) and seronegative. Demographics, comorbidities, RA-spesific treatments and nodule characteristics were compared.ResultsOf 680 RA patients who had pulmonary nodule in chest CT, 208 (30.6%) patients were classified as having pulmonary rheumatoid nodule. 167 (80.3%) patients were seropositive. Demographic and comorbidity characteristics were similar among seronegative and seropositive patients (Table 1). Regarding RA-spesific treatments, methotrexate, leflunomide and rituximab were prescribed more frequently in seropositive patients. For nodule characteristics, seropositive patients had higher number of nodules (5 [1-48] vs 3 [1-27]; p=0.004), bigger dominant nodule (8 [3-95] vs 6 [3-45] mm; p=0.011), and higher percentage of cavitary nodule (28.7% vs 12.2%; p=0.03). Localization of the nodule was compareble.Table 1.Comparison of demographic, disease and nodule characteristics of seropositive and seronegative patients (n=208)Seropositive (n=167, 80.3%)Seronegative (n=41, 19.7%)P valueFemale, n(%)113 (67.7)28 (68.3)0.94Age at the time of CT (median, min-max)61 (24-83)59.7 (20-83)0.28Smoking (n=73)26 (43.3)4 (30.8)0.40- Never smoked34 (56.7)9 (69.2)- Ever smokedComorbidity (n=188)127 (84.7)30 (78.9)0.40- Hypertension72 (55.0)18 (58.1)0.91- Diabetes (n=166)25 (18.5)7 (22.6)0.79- CAD (n=165)30 (22.6)7 (21.9)0.93- Heart Failure (n=164)15 (11.4)6 (18.8)0.41- COPD (n=163)20 (15.2)1 (3.2)0.13- Asthma (n=160)15 (11.6)5 (16.1)0.54- CKD (n=169)20 (14.5)8 (25.8)0.22- ILD (n=202)54 (33.1)10 (25.6)0.37RA-spesific treatments (ever)90 (72.6)16 (55.2)0.07- Methotrexate (n=153)105 (64.0)12 (30.8)0.001- Leflunomide (n=208)117 (70.5)25 (61.0)0.06- Hydroxchloroquine (n=169)65 (47.4)11 (36.7)0.28- Sulfasalazine (n=167)39 (39.0)6 (27.3)0.30- TNFi (n=122)41 (39.8)2 (9.5)0.008- Rituximab (n=124)11 (9.9)2 (8.0)0.77- Tofacitinib (n=136)12 (11.9)2 (10.5)0.86- Abatacept (n=120)9 (8.5)2 (8.7)0.98- Tocilizumab (n=129)Number of nodules at baseline CT (median, min-max)5 (1-48)3 (1-27)0.004Diameter of dominant nodule (median, min-max) (mm)8 (3-95)6 (3-45)0.011Localization of dominant nodul64 (38.3)15 (36.6)0.84- Left or right?64 (38.3)12 (29.3)0.48◦ Left51 (30.5)16 (39.0)0.28- Upper, middle or lower?52 (31.1)13 (31.7)◦ Upper69 (41.3)21 (51.2)◦ Middle22 (13.2)7 (17.1)◦ Lower76 (45.5)13 (31.7)-Peripheral, central or subpleural◦ Peripheral◦ Central◦ SubpleuralCavitation48 (28.7)5 (12.2)0.03Calcification54 (32.5)12 (29.3)0.69CAD: Coronary artery disease, CKD: Chronic kidney disease,; ILD: Interstitial Lung Disaese,ConclusionAutoantibodies seem to have impact on the characteristics of pulmonary rheumatoid nodules. As there were different prescription patterns were seen in our study, effects of these treatment differences need to be determined.ReferencesDisclosure of InterestsNone declared
- Published
- 2022
39. AB0355 THE DIFFERENCES BETWEEN THE FIRST PREFERRED BIOLOGICAL DMARD AND THE DRUG SURVIVAL IN GERIATRIC AND YOUNGER ADULT POPULATION WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS: TREASURE REAL-LIFE DATA
- Author
-
E. Gönüllü, U. Kalyoncu, B. Yağiz, A. Ateş, O. Küçükşahin, Ş. Yaşar Bilge, N. A. Kanitez, M. Çinar, D. Ersözlü, R. Mercan, S. Akar, T. Kaşifoğlu, B. N. Coşkun, S. S. Koca, E. Bilgin, V. Yazisiz, E. Dalkiliç, R. Yilmaz, G. Kimyon, S. M. Türk, A. Erden, C. Bes, H. Emmungil, Y. Pehlivan, A. İ. Ertenli, and S. Kiraz
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundInflammatory musculoskeletal diseases are frequent in the elderly population, and this number is expected to increase significantly near future. The exclusion of older adults from the studies due to their age and comorbidities causes insufficient data about this population. Insufficient data cause clinicians to have difficulties using and selecting biological therapy in the elderly patient group. In real life, physicians’ approaches to the selection and use of biological disease modifying anti-rheumatic drugs (DMARDs) in the geriatric population with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) have not been well studied.ObjectivesTo compare the clinicians’ first choice of biological DMARDs in elderly and younger RA and PsA patients and investigate the drug survival of first biological DMARDs in both populations.MethodsThe traditional chronological age for the human to be classified in the geriatric population is ≥ 65 years (1). The TReasure web-based registry, created in 2017, is a multicenter observational cohort established to collect data on RA and spondyloarthritis (SpA) patients from the participating 17 rheumatology centers in different regions of Turkey. Physicians’ first choice biological and targeted synthetic DMARDs in younger and elderly patients with RA and PsA was evaluated using the descriptive statistical method. The survival of the first b/tsDMARDs was assessed using the Kaplan-Meier method.Results3136 RA and 738 PsA patients were evaluated. 12% of 3136 patients with RA were in the geriatric population. In patients with RA, the first choice of biologic DMARDs was adalimumab (20.6%), followed by etanercept (19.9%), and tofacitinib (13.6%) in patients < 65 years of age, while rituximab (24%) was the first choice in patients ≥ 65 years, tofacitinib (20.9%) in the second place and etanercept (13%) in the third. Of 738 PsA patients, 3% were over 65 years. Adalimumab (41.1%) was the first choice of Figure 1.Comparison of first bDMARD retention rates between ConclusionWith these findings, it is thought that in Turkey, the limited socioeconomic support in the geriatric patients has led physicians to prescribe treatments such as rituximab, which are administered in the hospital under the supervision of a physician, are relatively preferred in malignancies, and are considered to be relatively less risky in terms of tuberculosis. Adalimumab and etanercept were chosen in the first two lines in both geriatric and young populations in the patient group with PsA. While the drug survival was significantly higher in patients with RA geriatric age group than the younger group, in PsA in which tumor necrosis factor-alpha (TNF-α) inhibitors were chosen as initial therapy in both age groups was lower in the geriatric population.References[1]Kotsani et al. JCM 2021. https://doi.org/10.3390/jcm10143018Disclosure of InterestsNone declared
- Published
- 2022
40. AB0277 DYSLIPIDEMIA TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS USING bDMARDs IS BETTER THAN PsA, BUT THERE IS STILL A WAY TO GO
- Author
-
G. Sandal Uzun, O. D. Tatar, N. E. Gezerer, E. Bilgin, G. K. Yardimci, E. C. Bolek, B. Farisogullari, E. Duran, Z. Özsoy, G. Ayan, M. Ekici, E. Unaldi, L. Kiliç, A. Akdoğan, O. Karadag, Ş. A. Bilgen, S. Kiraz, U. Kalyoncu, and A. İ. Ertenli
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundPatients with inflammatory arthritis have an increased risk of cardiovascular disease. Dyslipidemia is one of the primary modifiable risk factors.ObjectivesComparasion of the frequency of dyslipidemia and the use of anti-hyperlipidemic agents in patients with Rheumatoid Arthritis (RA) and Psoriatic arthritis (PsA) receiving bDMARDs.MethodsThe Hacettepe University biological database (HUR-BIO), was established in 2005 and 581 (75.4% female) patients with RA and 520 (69.4% female) patients with PsA enrolled up to 2021 were analyzed. Dyslipidemia was defined according to the Turkish Endocrine and Metabolism society criteria (TC > 240, Triglycerides (Tg) > 150, LDL-C > 160, HDL-C (< 40 in men, < 50 in women) (1). The anti-hyperlipidemic (anti-HL) agents used by the patients during follow-up and at their last visit were recorded.ResultsThe mean (SD) age of the patients and diseases duration were as follows; RA vs. PsA [age: 52.1 (13.9) vs. 48.7 (12.5) years; disease duration: 5.3 (2.1) vs. 9.2 (6.4) years]. Lipid profiles were known in 289 (49.7%) patients with RA and in 175 (33.6%) patients with PsA at the initiaiton of bDMARD. Lipid profiles were evaluated in 356 (61.2%) patients with RA and 226 (43.4%) patients with PsA during follow-up and at the last visit. Lipid profiles were similar in patients with RA and PsA at the initiation of bDMARDs (Table 1). At the initiation of bDMARD, 29 (5.0%) of RA patients and 10 (3.2%) of PsA patients were receiving anti-HL agents. During the entire follow-up, 65 (12.6%) patients with RA and 22 (4.8%) patients with PsA have used anti-HL agents (pTable 1.Lipid values in patients with RA and PsA at the initiation of bDMARD and at the last visitRheumatoid arthritis, n (%)Psoriatic arthritis, n (%)p1*p2**Lipid valuesbDMARD initiationLast visitbDMARD initiationLast visitTotal Cholesterol> 24047/270(17.4)98/339 (28.9)32/161(19.8)57/203 (28.1)0.300.13Triglyseride> 15062/242 (25.6)108/320 (33.7)45/159 (28.3)80/193 (41.4)0.790.20HDL-C< 40 (males),< 50 (females)88/267 (32.9)70/343 (20.4)57/157 (36.3)20/207 (9.6)0.480.001LDL-C > 16053/289 (18.3)91/356 (25.6)43/175 (24.5)65/226 (28.7)0.380.55*p1, bDMARD initiation visit comparison**p2, last visit comparisonConclusionIn real-life cohort, lipid profile was not assesed in half of the patients during entire follow-up. Although, LDL-C levels are high in about a quarter of the patients in both groups, use of anti-hyperlipidemic drug was inadequate. This is even more evident in PsA patients. Despite the significant emphasis on comorbidities in treatment guidelines, there is still a long way to go in real life.References[1]TEMD Obesity Guideline, L.M., Hypertension Working Group, TEMD Dyslipidemia Diagnosis and Treatment Guideline. 9th ed. 2021,Disclosure of InterestsNone declared
- Published
- 2022
41. AB0843 OSTEOPOROSIS IN PATIENTS WITH SPONDYLOARTHRITIS: DO WE NEED TO DO MORE?
- Author
-
Z. Özsoy, K. Moral, F. Yeşil, E. Bilgin, E. C. Bolek, G. K. Yardimci, B. Farisogullari, E. Duran, G. Ayan, G. Sandal Uzun, M. Ekici, E. Unaldi, L. Kiliç, A. Akdoğan, O. Karadag, Ş. A. Bilgen, S. Kiraz, A. İ. Ertenli, and U. Kalyoncu
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundData regarding the prevalence and especially incidence of osteoporosis in Spondylarthritis (SPA) is scarce and very divergent among studies from different patient populations (1).ObjectivesIn this study, we aimed to compare demographic, disease and laboratory characteristics of SpA patients regarding their bone mineral densitometry (BMD) categories and find out incidence of osteoporosis in the follow-up BMD of patients who were not found to have osteoporosis at baseline.MethodsBetween 2010-2021, patients with a SPA diagnosis in the HUR-BIO database were searched. HUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single center biological disease modifying anti-rheumatic drug (DMARD) registry since 2010. Patients with BMD measurement were included in the study. Follow-up BMD scores were also documented. The patients were divided into 3 groups as normal, osteopenia and osteoporosis in accordance with the WHO criteria (2). Demographic characteristics, comorbidities, laboratory data and drugs in each group were documented.Results3245 patients were reviewed. BMD was measured at least once in 118 patients out of 3245 (3.6%) patients. When the groups classified, 34 patients (28.8%) were included in the normal, 49 (41.5%) osteopenia and 35 (29.7%) osteoporosis groups. Patients with normal BMD was younger than both groups. Diabetes and hypertension were more prevalent in patients with osteopenia. The BMI was significantly lower in the osteoporosis group. 25 patients with normal and osteopenia in baseline BMD measurement had at least 1 follow-up BMD measurement. During the total follow-up of 91 patient-years, 3 patients had osteoporosis, revealing a the incidence of 3.3% in 100 patient-years.ConclusionIn our study, the incidence of OP development in SPA patients was found to be 3.3%. Frequency of osteoporosis was 29.7% among SpA patients with BMD measurement (118/3245; 3.6%), however; only 40% of them had appropriate treatment. Osteoporosis seems as an overlooked and undertreated comorbidity of SpA.Table 1.Comparison of spondyloarthritis patients according to BMD scores (normal, osteopenia and osteoporosis) according to baseline BMD assessmentNORMAL Number, (%)OSTEOPENIA Number, (%)OSTEOPOROSIS Number, (%)P VALUENumber of Patients34 (28.8)49 (41.5)35(29.7)Age47,5 (27-70)63 (45-79)58 (20-75)0.00*Gender (Female)24 (70.6)34 (69.4)23 (65.7)Diabetes Mellitus3 (8.8)14 (29.2)1 (2.9)0.00*Hypertension11 (32.4)28 (58.3)5 (14.3)0.00*Chronic Renal Failure2 (6.9)1 (2.7)1 (5.3)0.81Chronic Ostructive Pulmonary Disease4 (13.8)4 (10.8)1 (5.3)0.30Coronary Artery Disease0 (0)5 (12.5)3 (15)0.27Malignancy1 (3.6)1 (2.9)1 (4.2)1.0Smoking21 (61.8)23 (47.9)21 (63.6)0.379 (26.5)13 (27.1)5 (15.2)4 (11.8)12 (25)7 (21.2)Calcium mg/dl9.4 (8.2-10.2)9.5 (8.7-10.4)9.7 (8.1-10.4)0.49Phosphorus mg/dl3.5 (3-4.4)3.4 (2.6-5)3.8 (2.9-4.9)0.25Vitamin D ng/ml16 (7.4-64.4)21.2 (5-69.6)15.8 (5.8-49.1)0.66ALP IU/ml89.5 (54-137)89.5(53-169)80 (50-239)0.43Albumin g/dl4.2 (1.7-4.7)4.2 (3.3-8.4)4.2 (2-4.8)0.43TSH mU/ml1.5 (0.8-4.1)2.3 (0.1-9.7)2 (0.7-3.3)0.71Body Mass Index (BMI) kg/m229 (17-41.2)28.3 (20-44.6)25.1(15.8-43.2)0,06*Steroids4 (11.8)8 (16.3)2 (5.7)0.33Anti-TNF25 (73.5)35 (71.4)26 (74.3)0,95D Vitamin7 (20.6)14 (28.6)10 (28.6)0.67Calcium4 (11.8)5 (10.2)6 (17.1)0.63Bisphosphonate0 (0)4 (8.2)14 (40)0,00*Data was represented as median (minimum-maximum) or n(%)References[1]Hu LY, Chen PM, Shen CC, et all. Should clinicians pay more attention to the potential underdiagnosis of osteoporosis in patients with ankylosing spondylitis? A national population-based study in Taiwan. PoleS one 2019:6;14[2]Kanis JA on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK. 2007: Printed by the University of Sheffield.Disclosure of InterestsNone declared
- Published
- 2022
42. POS0944 PREDICTORS OF SUSTAINED REMISSION IN PEOPLE WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIOLOGIC DRUGS
- Author
-
B. Farisogullari, G. K. Yardimci, E. Bilgin, E. C. Bolek, E. Duran, G. Ayan, Z. Özsoy, G. Sandal Uzun, M. Ekici, E. Unaldi, L. Kiliç, A. Akdoğan, O. Karadag, Ş. A. Bilgen, S. Kiraz, A. İ. Ertenli, U. Kalyoncu, and P. M. Machado
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundThe ultimate goal of treatment in axial spondyloarthritis (axSpA) is sustained remission. Data on predictors of sustained remission are scarce in axSpA.ObjectivesTo determine predictors of sustained remission in people with axSpA after treatment with their first biological disease-modifying anti-rheumatic drug (bDMARD).MethodsHacettepe University Rheumatology Biologic Registry (HUR-BIO) is a prospective, single center registry of rheumatic disease patients treated with bDMARDs. Patients with axSpA were selected and sustained remission defined as attainment of Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) and/or Ankylosing Spondylitis (AS) Disease Activity Score C-reactive protein Inactive Disease (ASDAS-ID) for two or more consecutive visits spanning ≥6 months during follow-up. Patients achieving and not achieving sustained remission were compared using the independent t-test. Multivariable logistic regression analysis was performed to determine independent factors predictive of sustained remission. Variables with a p-valueResultsData on 990 patients with sustained remission data were available. Of these, 299 (30%) were in sustained remission, while 691 (70%) were not. Patients in sustained remission were younger, had earlier disease onset, were more frequently male, had lower BMI and were more frequently HLA-B27 positive, compared to patients not in sustained remission. Furthermore, at the start of bDMARD treatment, Bath AS Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), and patient global assessment (PGA, 0-10 scale) were lower, while acute phase reactants (ESR and CRP) were higher, in the sustained remission group. In multivariable analysis, male gender (OR 2.2, 95% CI 1.21-3.95), concomitant conventional synthetic DMARD (csDMARD) use (OR 3.63, 95% CI 1.29-10.19), PGA (OR 0.96, 95% CI 0.95-0.98), and early achievement (between 3-6 months) of remission (OR 13.1, 95% CI 7.13-24.02) were independently associated with sustained remission (Table 1, model 1). In the model without the variable early achievement of remission (Table 1, model 2), similar and a few additional associations were described: age at diagnosis (OR 0.97, 95% CI 0.96-0.99), male gender (OR 2.31, 95% CI 1.60-3.35), concomitant csDMARD use (OR 1.88 95% CI 1.23-2.86), PGA (OR 0.98, 95% CI 0.97-0.99), BASDAI (OR 0.87, 95% CI 0.78-0.96), and baseline symptom duration (OR 0.97, 95% CI 0.94-0.99).Table 1.Multivariable analysis (best-fit model) of predictors of sustained remissionModel 1Model 2CovariatesMultivariable Analysis (n= 541)Multivariable Analysis (n=739)OR (95% CI)p-valueOR (95% CI)p-valueAge at diagnosisNSNS0.97 (0.96-0.99)0.006Male sex2.84 (1.71-4.70)2.31 (1.60-3.35)Concomitant csDMARD use (at baseline or follow-up)2.94 (1.57-5.51)0.0011.88 (1.23-2.86)0.003Baseline PGA0.97 (0.96-0.98)0.98 (0.97-0.99)0.002Baseline BASDAINSNS0.87 (0.78-0.96)0.009Baseline symptom durationNSNS0.97 (0.94-0.99)0.021Achievement of remission at 3-6 months after baseline11.70 (7.11-19.23)NANANA: not applicable; NS: not selected (not contributing to the model). Baseline refers to start of bDMARD treatment.ConclusionThis study demonstrates that patients in sustained remission after starting bDMARD treatment have distinctive characteristics compared to patients not in sustained remission. These data can be used to aid clinical and personalized management of axSpA, and to facilitate better communicate between health care professionals and patients regarding the course and prognosis of their condition.Disclosure of InterestsBayram Farisogullari: None declared, Gözde Kübra Yardimci: None declared, Emre Bilgin: None declared, Ertugrul Cagri Bolek: None declared, Emine Duran: None declared, Gizem Ayan: None declared, Zehra Özsoy: None declared, Gullu Sandal Uzun: None declared, Mustafa Ekici: None declared, Erdinc Unaldi: None declared, Levent Kiliç: None declared, Ali Akdoğan: None declared, Omer Karadag: None declared, Şule Apraş Bilgen: None declared, Sedat Kiraz: None declared, Ali İhsan Ertenli: None declared, Umut Kalyoncu: None declared, Pedro M Machado Speakers bureau: Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, Consultant of: Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB
- Published
- 2022
43. POS1440 HEMATOLOGICAL MALIGNANCIES AND ANTI-TNF IN INFLAMMATORY ARTHRITIS: THE REAL LIFE DATA FROM THE HUR-BIO REGISTRY
- Author
-
E. Duran, Z. Ö. Öztürk, E. Bilgin, E. C. Bolek, G. K. Yardimci, B. Farisogullari, Z. Özsoy, G. Ayan, G. Sandal Uzun, M. Ekici, E. Unaldi, L. Kiliç, A. Akdoğan, O. Karadag, Ş. A. Bilgen, S. Kiraz, U. Kalyoncu, and A. I. Ertenli
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundTNF inhibitors (TNFi) is highly effective in inflammatory arthritis (IA) treatment. However, concerns are raised about the possible association between TNFi and hematologic malignancies (HMs).ObjectivesTo assess the incidence of HMs among IA patients receiving TNFi compared with the general Turkish population.MethodsHUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single center biological disease modifying anti-rheumatic drug (bDMARD) registry since 2005. Patients with IA including rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA) patients who had at least 1 visit after the TNFi usage were screened from 2005 to November 2021. HM diagnosis was determined from the each patient files according to the hematologists’ decision and/or bone marrow/lymph node biopsy. Demografic data, disease characteristics, and death status were recorded. Standardized incidence rates (SIR) were calculated after adjustment for age and gender and compared with age- and gender-specific SIR values abstracted from the 2017 Turkish National Cancer Registry (TNCR).ResultsOf the 6139 patients registered in the HUR-BIO database, 5355 [3116 female (58.2%)] used any TNFi at least once. Median follow-up duration was 2.6 years for all patients receiving TNFi. 13 patients [8 (61.5%) female] had HM on follow-up. In these patients, median age at the IA onset was 38 (range 26 to 67) and the number of patients with SpA, RA, and PsA was 7, 4, and 2, respectively. The median duration of IA was 17.7 years (range 1 to 33). The median age at the HM onset was 55.5 (range 38 to 76) and the type of HM as follow: 8 lymphoma, 2 multiple myeloma, 1 large granular lymphocytic leukemia, 1 plasma cell dyscrasia, and 1 myelodysplastic syndrome. The median duration of the TNFi usage onset to HM was 36 (range 4-112) months. The TNFi was as follows: etanercept (n=8), adalimumab (n=6), infliximab (n=4), golimumab (n=1), and certolizumab (n=1). 5 patients used more than one TNFi. Patients using TNFi had an increased incidence for HMs (SIR 4.23, 95% CI 2.35-7.05). These results were also valid for both gender. 10 patients with HMs were under the age of 65. In this group, there was a higher incidence of HMs in both men (SIR 5.15, 95% CI 1.88-11.43) and women (SIR 4.76, 95% CI 1.74-10.55). 5 patients deceased on follow-up.ConclusionThe risk of HMs in inflammatory arthritis patients receiving TNFi being four times higher in comparison with the general Turkish population. There is a plethora of information that discusses the association between HMs and rheumatic disease. To determine whether the increased risk is from rheumatic disease or from TNFi usage, it would be ideal to compare patients receiving TNFi with bDMARD naive IA patients.Table 1.SIR for diferent age cut-ofs in both sexes for patients with hematologic malignanciesGenderAgeObserved/expected casesSIR%95 confidence intervalTotalAll ages*13/3.074.232.35-7.05Male20-64 years (n=2059)5/0.975.151.88-11.43≥ 65 years (n=180)0/0.39NA-Overall (n=2239)5/1.363.671.34-8.14Female20-64 years (n=2667)5/1.054.761.74-10.55≥ 65 years (n=449)3/0.664.541.15-12.37Overall (n=3116)8/1.714.672.17-8.88*: Includes patients ≥18 years.NA: Not applicable, SIR: standardized incidence ratesFigure 1.Cumulative number of hematologic malignancies in function of time from start of first anti-TNF therapyDisclosure of InterestsNone declared
- Published
- 2022
44. POS1184 EPIDEMIOLOGICAL CHARACTERISTICS OF VIRAL HEPATITIS IN PATIENTS WITH RHEUMATIC DISEASES – IMPLICATIONS FROM TREASURE DATABASE
- Author
-
D. Ersözlü, M. Ekici, B. N. Coşkun, S. Ö. Badak, E. Bilgin, U. Kalyoncu, B. Yağiz, Y. Pehlivan, O. Küçükşahin, A. Erden, D. Solmaz, P. Atagündüz, G. Kimyon, C. Bes, S. Colak, R. Mercan, T. Kaşifoğlu, H. Emmungil, N. A. Kanitez, A. Ateş, S. S. Koca, S. Kiraz, and A. İ. Ertenli
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundRecent epidemiological data on HBV and HCV in Turkey revealed that the seroprevalence rates of hepatitis B surface antigen and antibody against HCV were 4% and 1%, respectively, and seropositivity rates for hepatitis B surface antibody and hepatitis B core antibody were 31.9% and 30.6%, respectively. A previous multicenter nationwide study conducted in Turkey reported that the HBsAg positivity was determined in 2.3% of patients with rheumatoid arthritis (RA) and 3% of patients with ankylosing spondylitis (AS), and the anti-HCV positivity was detected in 1.1% of patients in each group. Given these rates, viral hepatitis is still considered a potential threat to patients with rheumatic diseases, specifically for the treatment-related viral reactivation.ObjectivesThis study aimed to evaluate the serologic HBV and HCV frequency and clinical characteristics among our patients with RA or SpA and receive biological treatments based on this background.MethodsThe prospective TReasure database, which observationally collects data of patients with rheumatic diseases from fifteen centers across Turkey, was analyzed for viral hepatitis, patient characteristics, and treatments used. TReasure registry study protocol, and the data collection was started on December 2017. At the time of the analysis for this study was performed, the registry database included 3147 patients with RA and 6071 patients with SpA. For hepatitis B; Hepatitis B surface antigen (HBsAg), anti-HBV core antibody (anti-HBc) and anti-HBV surface antibody (Anti-HBs) tests were evaluated. HBV-DNA was studied in HBsAg positive patients. Anti-HCV antibody has been studied for HCV. The clinical and serological HBV reactivation in the follow-up of the patients was evaluated by looking at the HBV-DNA viral loads.ResultsA total of 9218 patients (3147 RA and 6071 patients with SpA) were included in the analyses. The screening rate for HBV was 97% in RA and 94.2% in SpA groups. HBsAg positivity rates were 2.6% and 2%, anti-HBs positivity rates were 32.3% and 34%, anti-HBc positivity rates were 20.3% and 12.5%, HBV DNA positivity rates were 3.5% and 12.5%, and anti-HCV positivity rates were 0.8% and 0.3% in these groups, respectively (Table 1).Table 1.Serological analyses in the study groupRASpApNn (%)Nn (%)Hepatitis testing28962809 (97.0)54445130 (94.2)HBsAg positivity275071 (2.6)501799 (2)0.080Anti-HBs positivity2708876 (32.3)48931663 (34)0.147Anti-HBc positivity2362480 (20.3)4194524 (12.5)HBV-DNA positivity45416 (3.5)63735 (5.5)0.129Anti-HCV positivity260222 (0.8)462716 (0.3)0.005The HBsAg (+) patients were older and had higher comorbidities, including hypertension, diabetes, and coronary artery disease. In addition, RF positivity was more in HBsAg(+) cases. The most frequently prescribed bDMARDS were adalimumab (28.5%), etanercept (27%), tofacitinib (23.4%), and tocilizumab (21.5%) in the RA group, whereas adalimumab (48.1%), etanercept (31.4%), infliximab (22.6%), and certolizumab (21.1%) in the SpA group. HBV reactivation was observed in one patient with during RA treatment, who received rituximab and prophylaxis with tenofovir.Figure 1.Prescription proportions of medications in the rheumatoid arthritis (RA) and spondyloarthritis (SpA) groupsConclusionThe epidemiological characteristics of patients with rheumatic diseases and viral hepatitis are essential for effective patient management. This study provided the most recent epidemiological characteristics from the prospective TReasure database, one of the most comprehensive registries in rheumatology practice. According to the results of our study; It can be thought that there is no risk in the choice of treatment by the rheumatologist in patients who receive appropriate prophylaxis.Disclosure of InterestsNone declared
- Published
- 2022
45. AB0278 IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING bDMARDs, THE CHARLSON COMORBIDITY INDEX IS MORE PRONOUNCED THAN PSORIATIC ARTHRITIS
- Author
-
G. Sandal Uzun, O. D. Tatar, N. E. Gezerer, E. Bilgin, G. K. Yardimci, E. C. Bolek, B. Farisogullari, E. Duran, Z. Özsoy, G. Ayan, M. Ekici, E. Unaldi, L. Kiliç, U. Kalyoncu, O. Karadag, A. Akdoğan, Ş. A. Bilgen, S. Kiraz, and A. İ. Ertenli
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundAccording to international recommendations, co-morbidities must be taken into account in the management of patients with inflammatory arthritis.ObjectivesTo evaluate the distribution of pre-treatment comorbidities in the bDMARD cohort including patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).MethodsThe Hacettepe University biological database (HUR-BIO) was established in 2005, 581(75.4% female) patients with RA and 520 (69.4%female) patients with PsA enrolled up to 2021 were analyzed. Diagnosis of RA and PsA were based on the clinical evaluation of the rheumatologist who followed the patients. Comorbidities of the patients were reviewed retrospectively from the biological database, hospital electronic records, ICD-10 diagnostic codes and prescriptions of patients. Diabetes mellitus (DM), Hypertension (HT), Dyslipidemia (DL), Coronary artery disease (CAD), Body mass index (BMI) and smoking were recorded. DL was grouped in terms of lipid values according to the classification of the Turkish Society of Endocrinology and Metabolism Dyslipidemia Guide(1). Detection of coronary artery disease before the age of 55 in men and of 65 in women was classified as premature - CAD. Data on Chronic Kidney Disease, obstructive pulmonary disease, Cerebro-vascular disease, Thyroid Diseases were also recorded. The Charlson comorbidity index (CCI) was calculated by summing the comorbidities in the patients’ medical history before the bDMARDs.ResultsThe distribution of comorbidities in patients with RA and PsA prior to initiation of bDMARDs was given in Table 1. Patients with RA were older and smoking was more common. HT(28.5% for RA, 21.9% for PsA) and thyroid diseases (22.7% for RA, 14.7% for PsA) were the most comorbidities in both groups. Compared to PsA, patients with RA had higher rate of comorbidities (64.8% vs. 40.4%, pTable 1.Comorbidities in RA and PsA patientsFeaturesRA n=581PsA n=520pGender, female n (%)438 (75.4)361 (69.4)0.027Age at PsA diagnosis, mean (SD) years46.7 (13.7)39.3 (12.0)Age at bDMARD start, mean (SD) years49.5 (13.8)42.2 (12.3)CCI-No comorbidity205/581 (35.2)290/486 (59.6)-1 comorbidity145/581 (24.9)90/486 (18.5)-≥ 2 comorbidity231/581 (39.7)106/486 (21.8)CCI mean, (SD)1.56 (1.77)0.78 (1.18)Smoking (ever), n292/581282/506BMI, mean (SD)29.3 (6.7)29.6 (5.9)0.50BMI ≥ 30 n261/577221/4980.77Diabetes Mellitus, n68/58149/4020.30Hypertension, n166/581110/5020.012Dyslipidemia* n-High TC47/27032/1610.30-High TG62/24245/1590.79-High LDL -C53/289(43/1750.38-Low HDL-C88/26757/1570.48Uric acid (>6 mg/dl), n150/554136/4370.16CAD n59/52432/4860.010Premature CAD, n39/58118/4860.030CKD, nG1 (GFR > 90)437/5230G2 (GFR 60-90)68/5230G3a (GFR 45-60)11/5230G3b (GFR 30-45)5/52328/370G4 (GFR 15-30)2/523342/370Lung disease, n-COPD15/5193/4850.007-Asthma66/52019/485Thyroid disease, n132/58165/440*TC > 240, TG 150-499, LDL-C> 160, HDL-C erkek < 40, kadin < 50CCI: Charlson comorbidity index, CAD: Coronary artery disease, CKD: Chronic Kidney Disease, COPD: Chronic Obstructive pulmonary diseaseConclusionThe burden of comorbidities in patients with RA before bDMARDs is more pronounced than in patients with PsA. Although, cardiovascular risk factors were similar, with the exception of hypertension and smoking, the age-adjusted CCI was 3.96 times higher in patients with RA than in patients with PsA.References[1]TEMD Obesity Guideline, L.M., Hypertension Working Group, TEMD Dyslipidemia Diagnosis and Treatment Guideline. 9th ed. 2021Disclosure of InterestsNone declared
- Published
- 2022
46. POS1085 FREQUENCY OF DYSLIPIDEMIA AND COMPLIANCE WITH THE TREATMENT IN PsA PATIENTS USING bDMARDs
- Author
-
N. E. Gezerer, G. Ayan, E. Bilgin, G. K. Yardimci, E. C. Bolek, B. Farisogullari, E. Duran, Z. Özsoy, G. Sandal Uzun, M. Ekici, E. Unaldi, L. Kiliç, A. Akdogan, O. Karadag, Ş. A. Bilgen, S. Kiraz, A. İ. Ertenli, and U. Kalyoncu
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundDyslipidemia is the leading treatable-modifiable factor among comorbidities in Psoriatic arthritis (PsA) patients. International treatment recommendations have left the management of dyslipidemia to national guidelines and especially to the rheumatologists.ObjectivesIn this study, we aimed to determine the frequency of dyslipidemia and the rates of initiation of treatment within the indication in PsA patients using bDMARDs.MethodsThe Hacettepe University biological database (HUR-BIO), was established in 2005 and data of 520 PsA patients included until 2021 were analyzed. In all included patients, the diagnosis of PsA was made by therheumatologist. Lipid profiles of PsA patients were evaluated at diagnosis, during the first bDMARD initiation, and at the last visit. Total cholesterol (TC), Triglyserides (TG), HDL-C and LDL-C values were grouped as optimal, borderline, high and severely high according to the Turkish Endocrine and Metabolism society criteria (1).ResultsLipid profile values of PsA patients were known at diagnosis (n=159, 30.6%), in the initial bDMARD baseline (n=161, 30.9%), and at the last visit (n=203, 39.0%). The time to diagnosis of PsA and first bDMARD use was 2.8 years, and the time between the start of bDMARD and the last visit was 3.7 years. Accordingly, the rates of high TC, borderline TG, and high LDL increased over time. Rates at the time of PsA diagnosis, first bDMARD onset and at the last visit are as follows; high TC (14.3%, 17.1% and 28.0%), borderline TG (20.4%, 27.7% and 40.5%) and high LDL (17.0, 24.0% and 27.9%). On the other hand, low HDL-C slightly improved in men (33.3%, 29.4% and 23.1%), but did not show a significant change in women. While LDL-C level was >160 in 24.0% of patients who were started on bDMARD, anti-hyperlipidemic drug was started in only 6.2% of them. A similar situation persisted at the last visit (27.9% had LDL-C levels >160, but 10.8% received anti-hyperlipidemic therapy) (Table 1).Table 1.Lipid levels and changes over timeLipid levelsAt the time of diagnosis n= 159At the time of bDMARD initiation n=161bDMARD last visit n= 203Total Cholesterol (TC) mean (SD)195 (42)201 (43)214 (47)- TC < 200 (optimal) (%)56.552.845.3- TC 200-239 (borderline) (%)27.230.125.7-- TC > 240 (high) (%)14.317.128.0Triglyceride (TG) mean (SD)115 (52)132 (90)158 (103)- TG < 150 (optimal) (%)79.671.758.0- TG 150-499 (borderline) (%)20.427.740.5- TG 500-880 (high) (%)001.0-- TG ≥ 880 (severely high) (%)00.60.5HDL-C mean (SD)51.8 (13.1)50.6 (13.0)53.2 (12.5)- ≥60 (optimal) (%)20.620.425.6- 40-59 (borderline) in men (%)54.660.852.3- 50-59 (borderline) in women (%)32.324.530.3- Male < 40 (low) (%)33.329.423.1-- Women < 50 (low) (%)32.339.633.8LDL-C mean (SD)126 (33)132 (37)139 (36)- LDL-C < 100 (optimal) (%)21.421.114.2- LDL 130-159 (borderline) (%)22.525.127.0- LDL 160-190 (high) (%)17.024.027.9-- LDL > 190 (very high) (%)4.46.38.4Anti-hyperlipidemic drug n (%)5 (3.1)10 (6.2)22 (10.8)ConclusionAmong the modifiable risk factors for cardiovascular comorbidities in PsA patients, the leading risk factor is dyslipidemia. On the other hand, dyslipidemic drug use rates in daily practice are significantly lower. Although attention is paid to the management of comorbidities in all recommendations, there is still work to be done in real life.References[1]TEMD Obezite, L.M., Hipertansiyon Çalişma Grubu, TEMD DİSLİPİDEMİ TANI VE TEDAVİ KILAVUZU. 9 ed, ed. 2021, Ankara: Türkiye Endokrinoloji ve Metabolizma Derneği. 159.Disclosure of InterestsNone declared
- Published
- 2022
47. POS0977 ASSOCIATION OF DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER AND AXIAL SPONDYLOARTHRITIS WITH THE M694V MUTATION
- Author
-
M. Kiraci, E. Bilgin, E. Duran, B. Farisogullari, E. C. Bolek, G. K. Yardimci, Z. Özsoy, G. Ayan, G. Sandal Uzun, T. H. Akbaba, B. B. Peynircioglu, O. Karadag, A. Akdoğan, Ş. A. Bilgen, S. Kiraz, A. İ. Ertenli, U. Kalyoncu, and L. Kiliç
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundThe incidence of co-occurrence of FMF and axial spondyloarthritis (axSpA) in adults is reported to be 0.5-7.5%. M694V mutation is the most frequent variant in patients with FMF+AxSpA (1).ObjectivesTo evaluate the association of demographic and clinical characteristics of patients with FMF+axSpA with the M694V mutation.MethodsA total of 9630 FMF patients were identified according to the ICD-10 code (E85.0) in the electronic database of Hacettepe University Hospital. 7525 patients aged ResultsOf 113 patients with known MEFV gene result, 91 (80.5%) were M694V (+), 22 (19.5%) were M694V (-), 45 (39.8%) were homozygous for M694V. In the M694V (+) group, symptom onset and diagnosis of both FMF and axSpA were at an earlier age compared to M694V (-) patients (pTable 1.FeaturesM694V (+) (n=91)M694V (-) (n=22)P1M694V Homozygous (n=45)M694V Nonhomozygous (n=68)P2Age at FMF symptom onset [years, med (25-75)]11 (5-18)21 (8-30)0,0057 (1-42)18 (3-53)Age at FMF diagnosis [years, med (25-75)]18 (10-27)33 (27-38)12 (1-42)28 (3-59)Age at AxSpA symptom onset [years, med (25-75)]20 (15-25)29 (24-38)20 (5-50)22 (5-58)0,43Age at AxSpA diagnosis [years, med (25-75)]24 (19-33)37 (28-44)23 (11-51)29 (7-59)0,039Fever n (%)84 (92,3)21 (95,5)0,6044 (97,8)61 (89,7)0,10Abdominal pain n (%)80 (87,9)20 (90,9)0,7043 (95,6)57 (83,8)0,056Peripheral arthritis n (%)45 (49,5)7 (31,8)0,1324 (53,3)28 (41,2)0,20Erysipelas n (%)19 (20,9)2 (9,1)20,213 (28.9)8 (11,8)0,02Enthesitis n (%)21 (23,1)4 (18,2)0,6211 (24,4)14 (20,6)0,63Uveitis n (%)11 (12,1)4 (18,2)0,454 (8,9)11 (16,2)0,26Psoriasis n (%)6 (6,6)1 (4,5)0,722 (4,4)5 (7,4)0,82HLA-B27 (+) n (%)25 (27,3)4 (18,2)0,542/15 (13,3)12/40 (30)0,30Syndesmophyte n (%)20/82 (24,4)6/19 (31,6)0,527/43 (16,3)19/59 (32,2)0,07Total ankylosis n (%)4/83 (4,8)1/19 (5,3)0,941/43 (2,3)4/59 (6,8)0,39Moderate to severe hip disease*n (%)22 (24,2)2 (9,1)0,1212/45 (26,7)12 (17,6)0,25Total hip replacement n (%)10 (11,0)1 (4,5)0,364 (8,9)7 (10,3)0,80* BASRI-hip score ≥3 on any sideConclusionFMF and SpA symptoms appear at an earlier age in M694V positive patients. The M694V mutation is associated with severe disease and early disease onset.References[1]Kaşifoğlu T, Calişir C, Cansu DU, Korkmaz C. The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis. Clin Rheumatol. 2009;28(1):41-6.Disclosure of InterestsNone declared
- Published
- 2022
48. AB0353 bDMARD CHOICES FOR INFLAMMATORY ARTHRITIS WITH CHRONIC KIDNEY DISEASE; HUR-BIO REAL-LIFE REGISTRY
- Author
-
G. Sandal Uzun, A. Taghiyeva, İ. Y. Çakir, K. Moral, E. Bilgin, G. K. Yardimci, B. Farisogullari, E. C. Bolek, E. Duran, Z. Özsoy, G. Ayan, M. Ekici, E. Unaldi, L. Kiliç, A. Akdoğan, O. Karadag, Ş. A. Bilgen, S. Kiraz, A. İ. Ertenli, and U. Kalyoncu
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundRheumatic disesases may involve multiple systems and chronic kidney disease (CKD) can be seen during the course of diseases. Accompanying CKD affects the the choice of treatments in patients with rheumatic disease. There is limited data on the use of biological DMARDs in rheumatic patients with chronic kidney disease.ObjectivesTo determine the preferred first and second bDMARDs in patients in the CKD in the bDMARD cohort.MethodsThe Hacettepe University biological database (HUR-BIO), was established in 2005. A total of 2160 RA patients, 3744 SPA patients, were registered in HUR-BIO until November 2021. The CKD was confirmed and classified according to 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. . Patients were evaluated for the presence of CKB before the initiation of bDmard and during follow-up under bDMARDs. Age and sex matched RA patients without CKD were selected for the control group.Results142/5904 (2.4%) patients have CKD. 102(%71.8) patients had CKD prior to initiation of bDMARD and 40 (28.1%) patients had developed during follow-up. The median time to CKD development after starting bDMARD was 4.13 years(±4.05). Of the patients with CKD, 98 (69.0%) had RA and 44 (31.0%) had SpA. RA patients followed for CKD were older than SpA (66.0 (±11.1) vs 59.1 (±13.0) years, p=0.001), female gender was more common (73.5% vs 36.4%, pTable 1.Relationship between remission according to bDMARD and CKDRheumatoid arthritispSpondyloarthritispw CKD n=98wo CKD n=91w CKD n=44(%)wo CKD n=80(%)pEtanercept, n(%)34 (34.6)30 (33.0)0.4617 (38.6)22 (27.5)P=0.14Adalimumab, n(%)17(17.3)17 (18.7)0,4810 (22.7)22 (27.5)P=0.36Infliximab,n(%)3 (3)8 (8.8)0.8514(31.8)32 (40.0)p=0.24Golimumab, n(%)4 (4)3 (3.3)0,541 (2.2)3 (3.8)p=0.55Certolizumab, n(%)0 (0)3 (3.3)0,111 (2.2)1 (1.3)p=0.58Anti-TNF therapy, n(%)58 (59.2)61 (67.0)0,6143800.352Non-TNF biologics, n(%)40 (40,8)30 (33.0)0,13100.355Rituximab, n(%)14 (14.3)12 (13.2)0,57Abatacept, n(%)14(14.3)12 (13.2)0,49Tocilizumab, n(%)6 (6.1)10.0411(2.2)p=0.35Jak-kinase inhibitors, n(%)6(6.1)5 (5.5)0.55ConclusionIn our biologic cohort, 2% of patients with RA and SpA had accompanying CKD. In one-third of the patients with CKD, it was developed during the follow-up after bDMARDs. In patients with RA, there was no difference in terms of TNFi and non-TNF-i preferences. It should be kept in mind that CKD may develop during the follow-up of patients using bDMARDs.References[1]Ye W, Zhuang J, Yu Yet all Gender and chronic kidney disease in ankylosing spondylitis: a single-center retrospectively study. BMC Nephrol. 2019 Dec 9;20[2]Chebotareva NV, Guliaev SVet al. [Chronic kidney disease in rheumatoid arthritis patients: prevalence, risks factors, histopathological variants]. Ter Arkh. 2019 May 15;91(5)Disclosure of InterestsNone declared
- Published
- 2022
49. AB1076 IS THERE AN ADDITIONAL IMPACT OF STIMULATING CD8+ LYMPHOCYTES TO DETECT LATENT TUBERCULOSIS IN PATIENTS WITH RHEUMATIC DISEASES?
- Author
-
Z. Özsoy, A. Özdemir, M. Ekici, A. Eken, F. Çakmak, E. Bilgin, L. Kiliç, A. İ. Ertenli, Z. Saribaş, O. Karadag, and B. Şener
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundPurified protein derivative skin test (PPD) or interferon gamma release assays (IGRAs) are used as diagnostic tools to detect latent tuberculosis. QuantiFERON-TB Gold Plus (QFT-Plus) is a new test that detects latent tuberculosis. Antigens of Mycobacterium tuberculosis (ESAT-6 and CFP-10) are used. The test contains two tubes: TB1 and TB2. TB1 tube contains peptides of these antigens that induce CD4+T cell response while TB2 tube contains peptides designed to stimulate both CD4+ and CD8+ T cells. The amount of interferon gamma releases from those cells are determined by ELISA method. In patients with recent exposure to tuberculosis, there is an increased amount of CD8+ expression in comparison to patients with past exposure to tuberculosis.ObjectivesTo investigate the additional impact of stimulating CD8+ lymphocytes with QFT-Plus test in order to detect latent tuberculosis in patients with inflammatory rheumatic diseases.MethodsHacettepe University Rheumatology Biologic Registry Database (HURBIO) database was used in this study. QFT-Plus test of patients with rheumatoid arthritis (RA) and spondyloarthritis (SPA) between January 2018 and March 2021 during work up before biologic/targeted therapy were analysed, retrospectively. Positivity of any of tubes has been reported as QFT (+). The impact of each tube on QFT positivity is analysed.Results1480 patients (946 (64%) SPA, 534 (36%) RA) were enrolled. 957 patients were women. The median age was 45 (min-max:18-82). Totally 12.2% of patients had been reported as QFT(+). In 6% of QFT (+) patients only TB2 tube is positive (Table 1).Table 1.The impact of each tube on QFT-Plus positivityQFT-Plus test (n=1480)Negative86.2%Indeterminate1.5%PositiveOnly TB1 tube positivity8% of positively reported patients12.2% of all patientsOnly TB2 tube positivity6% of positively reported patientsTB1 and TB2 positivity86% of positively reported patientsConclusionDisease inflammatory cascades along with ongoing usage of immunosuppressive agents could affect results of QFT-plus assay in rheumatic diseases. TB2 tubes stimulating CD8(+) T lymphocytes have additional impact in detecting latent TB infection in patients with RA and SpA.Disclosure of InterestsNone declared
- Published
- 2022
50. POS1087 THE RELATIONSHIP BETWEEN CHANGES IN PSORIATIC ARTHRITIS DISEASE ACTIVITY AND COMORBIDITIES IN PATIENTS TREATED WITH bDMARDs
- Author
-
G. Ayan, N. E. Gezerer, E. Bilgin, G. K. Yardimci, E. C. Bolek, B. Farisogullari, E. Duran, Z. Özsoy, G. Sandal Uzun, M. Ekici, E. Unaldi, L. Kiliç, A. Akdogan, O. Karadag, Ş. A. Bilgen, S. Kiraz, A. İ. Ertenli, and U. Kalyoncu
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundComorbidities are common in psoriatic disease, needed to be recognized and managed to effectively when treating psoriatic arthritis (PsA) patients. However, the data on the impact of particular comorbidities on the disease activity in patients requiring bDMARDs are very small.ObjectivesOur aim was to understand the relationship between the disease activity and comorbidities in PsA patients under bDMARDs.MethodsThe Hacettepe University biological database (HUR-BIO), was established in 2005 and data of 520 PsA patients included until 2021 were analyzed. In all included patients, the diagnosis of PsA was made by the rheumatologist. DAS-28 score (at the last visit) and all comorbidities were documented after bDMARD initiation. Multivariate analysis was performed to understand comorbidities that have impact on DAS-28 remission.ResultsThere were 469 patients with a known DAS-28 score median (IQR) 28 (61) months after bDMARD initiation. It was detected in 214/469 (45.6%) patients with a DAS-28 score below 2.6. Patients in remission of DAS-28 were younger, remission was less frequent in women, and comorbidities, mainly BMI, Diabetes Mellitus (DM) and hypertension, were also found less frequent (Table 1). In the multivariate analysis, no determining factor was found in male gender. On the other hand, in females, smoking, presence of comorbidity, Body mass index (BMI) at the start of bDMARDs, age at onset of bDMARDs, DM at the start of bDMARDs, HT at the start of bDMARDs, coronary artery disease, and cardiovascular risk factors were included in the analysis and revealed, bDMARD baseline BMI [OR 1.06 (95% CI 1.02-1.11), p= 0.004] and presence of bDMARD baseline DM [OR 3.08 (95% CI 1.14-8.30), p=0.026] had significant impact on DAS-28 remission.Table 1.Relationship between remission according to DAS-28 score and comorbiditiesParametersDAS-28 ≤ 2.6 (n=214)DAS-28 > 2.6 (n=255)pAge, mean (SD), years43.8 (11.7)47.5 (12.5)0.001Age at PsA diagnosis, mean (SD), years36.8 (11.5)41.6 (11.7)Gender, female, n(%)115 (53.7)211 (82.7)Comorbidity count1.54 (0.98)1.98 (1.31)Comorbidity (yes/no)67 (31.9)118 (47.6)0.001Comorbidity distribution0.001-No143 (68.1)130 (52.4)-1 Comorbidity38 (18.1)47 (19.0)-≥ 2 Comorbidity17 (8.1)36 (14.5)-≥ 3 Comorbidity12 (5.7)35 (14.1)Body Mass Index (BMI)28.1 (5.4)30.3 (5.9)BMI > 30, n(%)70 (32.9)123 (48.4)0.001Diabetes Mellitus, n(%)10 (4.7)35 (13.7)0.001Hypertension, n(%)29 (13.6)71 (27.8)Total cholesterol > 240, n(%)8 (10.5)22 (28.6)0.019Thyroid Disease20 (9,8)43 (17,3)0,02ConclusionPrevious data showed that obesity, hypertension and at least 1 point from charlson comorbidity index are poor prognositc factors for treatment outcomes (1). Our data showed that BMI and presence of DM were determined as factors affecting bDMARD treatment response in female PsA patients.References[1]Ballegaard C, et al. Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study. Rheumatology (Oxford). 2021 Jul 1;60(7):3289-3300.Disclosure of InterestsNone declared
- Published
- 2022
Catalog
Books, media, physical & digital resourcesDiscovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.